LNCR3
MCID: LNG064
MIFTS: 78

Lung Cancer Susceptibility 3 (LNCR3)

Categories: Cancer diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lung Cancer Susceptibility 3

MalaCards integrated aliases for Lung Cancer Susceptibility 3:

Name: Lung Cancer Susceptibility 3 56 13 71
Lung Adenocarcinoma 12 52 29 6 15 17
Adenocarcinoma of Lung 56 12 74 43 71
Adenocarcinoma of Lung, Susceptibility to 56
Bronchogenic Lung Adenocarcinoma 12
Non-Small Cell Adenocarcinoma 71
Nonsmall Cell Adenocarcinoma 12
Lung Adenocarcinomas 15
Adenocarcinoma Lung 54
Lncr3 56

Classifications:



External Ids:

Disease Ontology 12 DOID:3910
OMIM 56 612571
MeSH 43 D000077192
NCIt 49 C27745 C3512
SNOMED-CT 67 254626006
UMLS 71 C0152013 C1335060 C2675497

Summaries for Lung Cancer Susceptibility 3

NIH Rare Diseases : 52 Lung adenocarcinoma is a cancer that occurs due to abnormal and uncontrolled cell growth in the lungs. It is a subtype of non-small cell lung cancer that is often diagnosed in an outer area of the lung. Early lung cancers may not be associated with any signs and symptoms. As the condition progresses, affected people can experience chest pain, a persistent cough, fatigue, coughing up blood, loss of appetite, unexplained weight loss, shortness of breath, and/or wheezing. The underlying cause of lung adenocarcinoma is generally unknown; however, risk factors for developing a lung cancer include smoking; exposure to secondhand smoke and other toxic chemicals; a family history of lung cancer; previous radiation treatment to the chest or breast; and HIV infection . Treatment varies based on the severity of the condition, the associated signs and symptoms and the affected person's overall health. It may include a combination of surgery, radiation therapy , chemotherapy , targeted therapy , and/or watchful waiting .

MalaCards based summary : Lung Cancer Susceptibility 3, also known as lung adenocarcinoma, is related to lung cancer and mucinous lung adenocarcinoma. An important gene associated with Lung Cancer Susceptibility 3 is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Signaling by GPCR and Innate Immune System. The drugs Endostar protein and Endostatins have been mentioned in the context of this disorder. Affiliated tissues include lung, brain and breast, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A lung cancer that derives from epithelial cells of glandular origin.

Wikipedia : 74 Adenocarcinoma of the lung is the most common type of lung cancer, and like other forms of lung cancer,... more...

More information from OMIM: 612571

Related Diseases for Lung Cancer Susceptibility 3

Diseases in the Lung Cancer Susceptibility 3 family:

Lung Cancer Susceptibility 1 Lung Cancer Susceptibility 4
Lung Cancer Susceptibility 5

Diseases related to Lung Cancer Susceptibility 3 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 883)
# Related Disease Score Top Affiliating Genes
1 lung cancer 36.7 TP53 STK11 SMAD4 ROS1 RAF1 PRKN
2 mucinous lung adenocarcinoma 35.8 ROS1 KRAS HRAS EGFR
3 lung squamous cell carcinoma 35.6 TP53 STK11 SMAD4 ROS1 PIK3CA NFE2L2
4 signet ring lung adenocarcinoma 35.4 EGFR ALK
5 adenocarcinoma 34.5 TP53 STK11 SMAD4 ROS1 RAF1 PIK3CA
6 hepatocellular carcinoma 33.4 TP53 STK11 SMAD4 RAF1 PIK3CA NRAS
7 pancreatic adenocarcinoma 33.3 TP53 SMAD4 RAF1 PIK3CA MAP2K1 KRAS
8 colorectal cancer 33.3 TP53 STK11 SMAD4 ROS1 RAF1 PIK3CA
9 breast cancer 33.3 TP53 STK11 SMAD4 RAF1 PIK3CA NRAS
10 sarcoma 33.2 TP53 ROS1 RAF1 PIK3CA NRAS MAP2K1
11 glioblastoma multiforme 33.2 TP53 ROS1 RAF1 PIK3CA NRAS MAP2K1
12 neuroblastoma 33.2 TP53 PRKN PIK3CA NRAS NFE2L2 MAP2K1
13 pancreatic cancer 33.1 TP53 STK11 SMAD4 RAF1 PIK3CA MAP2K1
14 prostate cancer 33.1 TP53 SMAD4 RAF1 PIK3CA NFE2L2 MAP2K1
15 gastric cancer 33.0 TP53 SMAD4 RAF1 PIK3CA NRAS NFE2L2
16 melanoma 33.0 TP53 STK11 RAF1 PIK3CA NRAS MAP2K1
17 bladder cancer 33.0 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
18 esophageal cancer 32.9 TP53 STK11 SMAD4 PIK3CA KRAS HRAS
19 colon adenocarcinoma 32.9 TP53 SMAD4 PIK3CA NRAS KRAS ERBB2
20 squamous cell carcinoma 32.8 TP53 STK11 SMAD4 PIK3CA NFE2L2 MAP2K1
21 ovarian cancer 32.8 TP53 STK11 SMAD4 RAF1 PRKN PIK3CA
22 adenoma 32.8 TP53 SMAD4 PIK3CA KRAS CTNNB1 BRAF
23 large cell carcinoma 32.8 STK11 ROS1 KRAS HRAS ERBB2 EGFR
24 cholangiocarcinoma 32.7 TP53 SMAD4 ROS1 RAF1 PIK3CA KRAS
25 acute promyelocytic leukemia 32.7 TP53 SMAD4 PIK3CA NRAS NFE2L2 MAP2K1
26 cervical cancer 32.7 TP53 STK11 SMAD4 PIK3CA NFE2L2 HRAS
27 endometrial cancer 32.7 TP53 SMAD4 PIK3CA NRAS KRAS HRAS
28 li-fraumeni syndrome 32.7 TP53 STK11 SMAD4 KRAS HRAS ERBB2
29 gastric adenocarcinoma 32.6 TP53 SMAD4 ROS1 RAF1 PIK3CA NRAS
30 lynch syndrome 32.6 TP53 STK11 SMAD4 PIK3CA KRAS HRAS
31 small cell carcinoma 32.5 TP53 KRAS EGFR ALK
32 nasopharyngeal carcinoma 32.5 TP53 SMAD4 RAF1 PIK3CA NRAS HRAS
33 bladder urothelial carcinoma 32.5 TP53 PIK3CA NRAS NFE2L2 MAP2K1 KRAS
34 leukemia, chronic lymphocytic 32.5 TP53 PIK3CA NRAS KRAS HRAS ERBB2
35 renal cell carcinoma, nonpapillary 32.5 TP53 RAF1 PIK3CA NRAS HRAS EGFR
36 brain cancer 32.4 TP53 PIK3CA NRAS HRAS EGFR CTNNB1
37 colorectal adenocarcinoma 32.4 TP53 KRAS HRAS ERBB2 EGFR CTNNB1
38 melanoma, uveal 32.3 TP53 SMAD4 RAF1 PIK3CA NRAS MAP2K1
39 renal cell carcinoma, papillary, 1 32.3 TP53 PIK3CA NRAS NFE2L2 HRAS FGFR3
40 leukemia, acute myeloid 32.3 TP53 PIK3CA NRAS MAP2K1 KRAS HRAS
41 neurofibromatosis, type ii 32.2 TP53 HRAS ERBB2 EGFR CTNNB1
42 thyroid carcinoma 32.2 PIK3CA HRAS BRAF
43 suppression of tumorigenicity 12 32.2 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
44 ovarian serous cystadenocarcinoma 32.2 TP53 SMAD4 PIK3CA NRAS KRAS HRAS
45 lung adenoma 32.2 TP53 RAF1 KRAS HRAS EGFR
46 ovary adenocarcinoma 32.2 TP53 SMAD4 PIK3CA KRAS HRAS ERBB2
47 intrahepatic cholangiocarcinoma 32.2 TP53 SMAD4 KRAS ERBB2 EGFR CTNNB1
48 adenoid cystic carcinoma 32.2 TP53 PIK3CA KRAS HRAS ERBB2 EGFR
49 glioma 32.1 TP53 PIK3CA ERBB2 EGFR CDK4 BRAF
50 in situ carcinoma 32.1 TP53 PIK3CA HRAS ERBB2 EGFR CTNNB1

Graphical network of the top 20 diseases related to Lung Cancer Susceptibility 3:



Diseases related to Lung Cancer Susceptibility 3

Symptoms & Phenotypes for Lung Cancer Susceptibility 3

Clinical features from OMIM:

612571

GenomeRNAi Phenotypes related to Lung Cancer Susceptibility 3 according to GeneCards Suite gene sharing:

26 (show all 26)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 11.09 BRAF EGFR PIK3CA HRAS KRAS
2 Decreased viability GR00055-A-2 11.09 BRAF EGFR PIK3CA HRAS KRAS
3 Decreased viability GR00055-A-3 11.09 KRAS
4 Decreased viability GR00106-A-0 11.09 KRAS
5 Decreased viability GR00107-A-1 11.09 MAP2K1
6 Decreased viability GR00221-A-1 11.09 ALK EGFR PIK3CA FGFR3 HRAS NRAS
7 Decreased viability GR00221-A-2 11.09 PIK3CA FGFR3 HRAS KRAS RAF1 ROS1
8 Decreased viability GR00221-A-3 11.09 ERBB2 FGFR3 HRAS MAP2K1 NRAS
9 Decreased viability GR00221-A-4 11.09 ALK BRAF EGFR ERBB2 PIK3CA
10 Decreased viability GR00249-S 11.09 ALK BRAF FGFR3 ROS1
11 Decreased viability GR00301-A 11.09 BRAF KRAS RAF1
12 Decreased viability GR00342-S-1 11.09 ROS1
13 Decreased viability GR00381-A-1 11.09 BRAF KRAS
14 Decreased viability GR00402-S-2 11.09 PIK3CA RAF1
15 Decreased substrate adherent cell growth GR00193-A-1 10.25 STK11 RAF1 ROS1
16 Decreased substrate adherent cell growth GR00193-A-2 10.25 CDK4 ALK EGFR RAF1 ROS1
17 Decreased substrate adherent cell growth GR00193-A-3 10.25 BRAF CDK4 FGFR3 STK11
18 Decreased substrate adherent cell growth GR00193-A-4 10.25 BRAF CDK4
19 Decreased cell migration GR00055-A-1 10.2 ALK CDK4 FGFR3
20 Decreased cell migration GR00055-A-3 10.2 BRAF EGFR HRAS PIK3CA
21 Decreased cell–culture–derived Hepatitis C virus (HCVcc; Luc–Jc1) infection GR00234-A-2 9.73 BRAF CDK4 EGFR STK11
22 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.71 BRAF CDK4 EGFR STK11
23 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.67 ALK BRAF FGFR3 RAF1
24 Reduced mammosphere formation GR00396-S 9.56 BRAF CDK4 EGFR HRAS KRAS NFE2L2
25 Upregulation of Wnt/beta-catenin pathway after WNT3A stimulation GR00016-A 9.02 APC BRAF CDK4 ROS1 SMAD4
26 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.85 CTNNB1

MGI Mouse Phenotypes related to Lung Cancer Susceptibility 3:

45 (show all 27)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.58 APC BRAF CDK4 CTNNB1 EGFR ERBB2
2 growth/size/body region MP:0005378 10.57 ALK APC BRAF CDK4 CTNNB1 EGFR
3 behavior/neurological MP:0005386 10.56 ALK APC BRAF CDK4 CTNNB1 ERBB2
4 cardiovascular system MP:0005385 10.56 APC BRAF CDK4 CTNNB1 EGFR ERBB2
5 homeostasis/metabolism MP:0005376 10.54 ALK APC BRAF CDK4 CTNNB1 EGFR
6 integument MP:0010771 10.53 ALK APC BRAF CDK4 CTNNB1 EGFR
7 craniofacial MP:0005382 10.52 APC BRAF CDK4 CTNNB1 EGFR ERBB2
8 endocrine/exocrine gland MP:0005379 10.5 ALK APC BRAF CDK4 CTNNB1 EGFR
9 digestive/alimentary MP:0005381 10.49 APC BRAF CDK4 CTNNB1 EGFR ERBB2
10 mortality/aging MP:0010768 10.49 ALK APC BRAF CDK4 CTNNB1 EGFR
11 embryo MP:0005380 10.48 APC BRAF CDK4 CTNNB1 EGFR ERBB2
12 neoplasm MP:0002006 10.43 ALK APC BRAF CDK4 CTNNB1 EGFR
13 nervous system MP:0003631 10.41 ALK APC BRAF CDK4 CTNNB1 EGFR
14 immune system MP:0005387 10.4 APC BRAF CDK4 CTNNB1 EGFR FGFR3
15 hematopoietic system MP:0005397 10.39 APC BRAF CDK4 CTNNB1 EGFR FGFR3
16 normal MP:0002873 10.33 APC BRAF CDK4 CTNNB1 EGFR ERBB2
17 muscle MP:0005369 10.31 APC BRAF CDK4 CTNNB1 EGFR ERBB2
18 liver/biliary system MP:0005370 10.3 APC BRAF CDK4 CTNNB1 EGFR KRAS
19 hearing/vestibular/ear MP:0005377 10.24 APC BRAF CTNNB1 EGFR FGFR3 KRAS
20 limbs/digits/tail MP:0005371 10.24 APC BRAF CTNNB1 EGFR ERBB2 FGFR3
21 no phenotypic analysis MP:0003012 10.21 CTNNB1 EGFR FGFR3 HRAS KRAS NRAS
22 reproductive system MP:0005389 10.13 ALK APC BRAF CDK4 CTNNB1 EGFR
23 renal/urinary system MP:0005367 10.1 APC BRAF CDK4 CTNNB1 EGFR FGFR3
24 pigmentation MP:0001186 10.02 ALK APC BRAF CDK4 CTNNB1 EGFR
25 respiratory system MP:0005388 9.97 ALK BRAF CTNNB1 EGFR ERBB2 FGFR3
26 skeleton MP:0005390 9.91 ALK APC BRAF CDK4 CTNNB1 EGFR
27 vision/eye MP:0005391 9.47 ALK APC BRAF CDK4 CTNNB1 EGFR

Drugs & Therapeutics for Lung Cancer Susceptibility 3

Drugs for Lung Cancer Susceptibility 3 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 182)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Endostar protein Phase 4
2 Endostatins Phase 4 71581480
3
Gefitinib Approved, Investigational Phase 3 184475-35-2 123631
4
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
5
Ipilimumab Approved Phase 3 477202-00-9
6
Ceritinib Approved Phase 3 1032900-25-6
7
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
8
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 54677470 5281106
9
Pembrolizumab Approved Phase 3 1374853-91-4
10
Pemetrexed Approved, Investigational Phase 3 137281-23-3, 150399-23-8 60843 446556
11
leucovorin Approved Phase 3 58-05-9 6006 143
12
Bevacizumab Approved, Investigational Phase 3 216974-75-3
13
Xylometazoline Approved, Investigational Phase 3 526-36-3 5709
14
Gemcitabine Approved Phase 3 95058-81-4 60750
15
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
16
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
17
Celecoxib Approved, Investigational Phase 3 169590-42-5 2662
18
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
19
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
20
Cobalamin Experimental Phase 3 13408-78-1 6857388
21 Shark Cartilage Phase 3
22 2,2'-dithiodiethanesulfonic acid Phase 3
23 Immunoglobulins, Intravenous Phase 3
24 Endothelial Growth Factors Phase 3
25 Immunoglobulin G Phase 3
26 Immunologic Factors Phase 2, Phase 3
27 Pharmaceutical Solutions Phase 2, Phase 3
28 Vaccines Phase 2, Phase 3
29 Anesthetics Phase 3
30 Liver Extracts Phase 3
31 Vitamin B Complex Phase 3
32 Folic Acid Antagonists Phase 3
33 Immunosuppressive Agents Phase 3
34 Folate Phase 3
35 Vitamin B9 Phase 3
36 Antirheumatic Agents Phase 3
37 Angiogenesis Inhibitors Phase 3
38 Antineoplastic Agents, Immunological Phase 3
39 Analgesics, Non-Narcotic Phase 3
40 Analgesics Phase 3
41 Cyclooxygenase Inhibitors Phase 3
42 Anti-Inflammatory Agents Phase 3
43 Anti-Inflammatory Agents, Non-Steroidal Phase 3
44 Anti-Infective Agents Phase 3
45 Antiviral Agents Phase 3
46 Antimetabolites Phase 3
47 Vitamins Phase 3
48 Vitamin B 12 Phase 3
49 Vitamin B12 Phase 3
50 Cyclooxygenase 2 Inhibitors Phase 3

Interventional clinical trials:

(show top 50) (show all 331)
# Name Status NCT ID Phase Drugs
1 Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma Unknown status NCT02399566 Phase 4 Erlotinib, Pemetrexed
2 Recombinant Human Endostatin Durative Transfusion Combined With Pemetrexed Plus Cisplatin or Carboplatin in the First-line Treatment of Advanced Lung Adenocarcinoma With Wild-type EGFR or ALK-negative Unknown status NCT02804646 Phase 4 recombinant human endostatin;pemetrexed plus cisplatin or carboplatin
3 A Randomized ,Opened, Prospective Controlled Trial of Clinical Effectiveness for Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With Epidermal Growth Factor Receptor Gene Mutation Unknown status NCT02283424 Phase 4 Icotinib;chemotherapy (Carboplatin and Docetaxel)
4 Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma: a Randomized, Open-label, Multicenter Study Unknown status NCT02103257 Phase 4 Sequential Icotinib Plus Chemotherapy;Icotinib
5 Randomized, Open Label, Positive Controlled, Multicenter Trial to Evaluate Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma Unknown status NCT01665417 Phase 4 Experimental;Chemotherapy;Chemotherapy
6 Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Untreated Advanced Non-small-cell Lung Cancer: a Randomized, Open-label Study Unknown status NCT02194556 Phase 4 Sequential and maintenance icotinib;Maintenance icotinib
7 Open Label Study of Erlotinib (Tarceva®) as Single Agent First Line Treatment of Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With Activating Epidermal Growth Factor Receptor (EGFR) Mutations Completed NCT01609543 Phase 4 erlotinib [Tarceva]
8 Safety and Efficacy of Nab-paclitaxel (Abraxane) in Combination With Carboplatin as First Line Treatment in Elderly Subjects With Advance Non-Small Cell Lung Cancer (NSCLC): A Phase IV, Randomized, Open-Label, Multicenter Study (Abound.70+) Completed NCT02151149 Phase 4 nab-paclitaxel;Carboplatin
9 Synergistic Real-World Study and Evidence-based Medicine Evaluation of Elemene Combined With Tyrosine Kinase Inhibitors(TKIs)in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC): Prospective Study Not yet recruiting NCT04401059 Phase 4 Elemene plus First-generation EGFR-TKIs;First-generation EGFR-TKIs
10 Pemetrexed Disodium and Cisplatin Chemotherapy Combined With Synchronous Gefitinib vs Chemotherapy Alone as Adjuvent Therapy in Patient With Stage II-IIIA, Epidermal Growth Factor Receptor Mutant Expressing Lung Adenocarcinoma Unknown status NCT02518802 Phase 3 Gefitinib;Pemetrexed
11 A Phase III, Multi-center, Randomized Trial of Pemetrexed and Gefitinib in Never-smoker and Adenocarcinoma Patients With Non-small Cell Lung Cancer Previously Treated With Platinum-based Chemotherapy Unknown status NCT01066195 Phase 3 iressa;alimta
12 A Randomized, Phase III Trial of Prophylactic Cranial Irradiation (PCI) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Are Nonprogressive on Gefitinib or Erlotinib Unknown status NCT00955695 Phase 3 erlotinib hydrochloride;gefitinib
13 Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation Completed NCT01719536 Phase 3 Icotinib;Chemotherapy
14 A Randomized Phase III Study of Gefitinib (IRESSATM) Versus Standard Chemotherapy (Gemcitabine Plus Cisplatin) as First-line Treatment for in Never Smokers Advance or Metastatic Adenocarcinoma of Lung Completed NCT00455936 Phase 3 Gefitinib
15 A PHASE III STUDY OF ADJUVANT CHEMOTHERAPY AFTER RESECTION FOR PATIENTS WITH T2N0 STAGE I NON-SMALL CELL CARCINOMA OF THE LUNG Completed NCT00002852 Phase 3 paclitaxel;carboplatin
16 A Phase III Trial of Cisplatin/Etoposide/Radiotherapy With Consolidation Docetaxel Followed by Maintenance Therapy With ZD1839 (NSC-715055) or Placebo in Patients With Inoperable Locally Advanced Stage III Non-Small Cell Lung Cancer Completed NCT00020709 Phase 3 cisplatin;docetaxel;etoposide;gefitinib
17 A Phase III Prospective Randomized, Double-Blind, Placebo-Controlled Trial of the Epidermal Growth Factor Receptor Antagonist, ZD1839 (IRESSA) in Completely Resected Primary Stage IB, II and IIIA Non-Small Cell Lung Cancer Completed NCT00049543 Phase 3 gefitinib
18 Randomized Phase II/III Trial of Paclitaxel Plus Carboplatin With or Without Bevacizumab (NSC #704865) in Patients With Advanced Nonsquamous NSCLC Completed NCT00021060 Phase 2, Phase 3 paclitaxel;carboplatin
19 Multicenter, Open-Ended, Double-Blind, Placebo-Controlled, Phase III Study of AE-941 in Addition to Combined Modality Treatment (Chemotherapy/Radiotherapy) for Locally Advanced Unresectable Non-Small Cell Lung Cancer Completed NCT00005838 Phase 3 shark cartilage extract AE-941;cisplatin;vinorelbine tartrate;carboplatin;paclitaxel
20 Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin Completed NCT00966914 Phase 3 Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel;Placebo in combination with cisplatin and docetaxel or paclitaxel
21 Phase III Randomized Comparison Study of Vinorelbine, Gemcitabine, and Docetaxel Versus Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3 carboplatin;docetaxel;gemcitabine hydrochloride;paclitaxel;vinorelbine tartrate
22 Intercalating and Maintenance Use of Iressa vs. Chemotherapy in Selected Advanced NSCLC: a Randomised Study Completed NCT01404260 Phase 3 Gefitinib;Gemcitabine +Carboplatin
23 Study of Chinese Medicine Plus Targeted Therapy Maintenance Versus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma: A Randomized Double-blind Controlled Clinical Trial Completed NCT02889692 Phase 3 YiQiFang;YangYinFang;YiQiYangYinFang;placebo granules;Erlotinib®;Gefitinib®;Icotinib®
24 Adjuvant Chemotherapy Versus Observation in Fully Resected Stage I Lung Adenocarcinoma With High Risk of Post-operative Recurrence Recruiting NCT03380468 Phase 2, Phase 3 cisplatin plus pemetrexed
25 Tyrosine-kinase Inhibitor (TKI) With or Without SBRT in Newly Diagnosed Advanced Staged Lung Adenocarcinoma Recruiting NCT02893332 Phase 3 TKI (Gefitinib or Tarceva )
26 A Multi-center Phase III Randomized Controlled Trial Comparing Between Adjuvant Chemotherapy and Observation in High Risk Patients With Completely Resected Stage Ib Lung Adenocarcinoma Recruiting NCT02281708 Phase 3 vinorelbine plus cisplatin
27 Randomized Phase III Trial of Local Consolidation Therapy (LCT) After Nivolumab and Ipilimumab for Immunotherapy-Naive Patients With Metastatic Non-Small Cell Lung Cancer (LONESTAR) -Strategic Alliance: BMS Recruiting NCT03391869 Phase 3
28 A Double-Blind, Randomized, Active-Controlled, Parallel-Group, Phase 3 Study to Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Recruiting NCT03676192 Phase 3 CT-16;Avastin
29 Icotinib as an Adjuvant Therapy for Stage II-IIIA Adenocarcinoma With EGFR Mutation: A Placebo-controlled, Randomized, Double-blind, Phase III Study Recruiting NCT02125240 Phase 3 Icotinib;Placebo
30 A Phase III, Randomized, Double-blind Study to Assess the Efficacy and Safety of Lazertinib Versus Gefitinib as the First-line Treatment in Patients With Epidermal Growth Factor Receptor Sensitizing Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Recruiting NCT04248829 Phase 3 Lazertinib 240 mg/160 mg;Gefitinib 250 mg;Lazertinib-matching placebo 240 mg/160 mg;Gefitinib-matching placebo 250 mg
31 Phase III Study to Evaluate the Optimal Timing of Postoperative Radiotherapy for High Risk of Locoregional Recurrence Patients With Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3 Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)
32 Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations Who Did Not Progress After Pemetrexed in Combination With Platinum-based Chemotherapy:a Single-arm, Open, Multicenter Clinical Study. Recruiting NCT03992885 Phase 3 Icotinib
33 A Randomized, Phase III Study Comparing Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Active, not recruiting NCT00946712 Phase 3 Carboplatin;Paclitaxel
34 A Phase III, Multicenter, Randomized, Open-label Study of Oral LDK378 Versus Standard Chemotherapy in Adult Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer Who Have Been Treated Previously With Chemotherapy (Platinum Doublet) and Crizotinib Active, not recruiting NCT01828112 Phase 3 Ceritinib;pemetrexed;docetaxel
35 A Phase III Multicenter, Randomized Study of Oral LDK378 Versus Standard Chemotherapy in Previously Untreated Adult Patients With ALK Rearranged (ALK-positive), Stage IIIB or IV, Non-squamous Non-small Cell Lung Cancer Active, not recruiting NCT01828099 Phase 3 Ceritinib;Pemetrexed;Cisplatin;Carboplatin
36 Clinical Study of Yiqi-yangyin-jiedu Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma Patients With Activating EGFR Mutation Enrolling by invitation NCT02929693 Phase 3 gefitinib;Yiqi-yangyin-jiedu decoction;placebo
37 Proteome-based Personalized Immunotherapy of Brain Metastases From Lung Cancer Enrolling by invitation NCT01782287 Phase 2, Phase 3
38 Comparison of Video-assisted Thoracoscopic Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion Not yet recruiting NCT02011997 Phase 3
39 Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in First-line Treatment for Patients With Metastatic Lung Adenocarcinoma: A Randomized Phase III Study Not yet recruiting NCT04339218 Phase 3 Pembrolizumab;Pemetrexed;Carboplatin
40 A Randomized, Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced Non-Small-Cell Lung Adenocarcinoma Terminated NCT01798485 Phase 3 Docetaxel;Ganetespib
41 Multicentric, Randomized, Phase III Trial Comparing 2 Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Asymptomatic Brain Metastases Terminated NCT02162537 Phase 3 Cisplatin;Pemetrexed;Bevacizumab
42 A Randomized Phase III Double Blind Trial Evaluating Selective COX-2 Inhibition in COX-2 Expressing Advanced Non-Small Cell Lung Cancer Terminated NCT01041781 Phase 3 carboplatin;celecoxib;gemcitabine hydrochloride;pemetrexed disodium
43 A Single-Arm Phase II Clinical Trial of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma Unknown status NCT03376737 Phase 2 Apatinib
44 The Use of CT Perfusion to Determine the Normalization Window Period in the Treatment of Advanced Primary Lung Adenocarcinoma With Endostar Unknown status NCT01564329 Phase 2 endostar
45 Chemotherapy Plus Gefitinib Versus Gefitinib Alone as First-line Treatment for Patients With Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial Unknown status NCT02951637 Phase 2 Pemetrexed plus carboplatin combined with gefitinib;Gefitinib
46 Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma: A Prospective, Randomised, Open, Multicenter Phase Ⅱ Study Unknown status NCT02621333 Phase 2 chemotherapy
47 High-dose Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases Unknown status NCT02284490 Phase 2 pemetrexed
48 A Phase II Trial of Hypofractionated Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy Unknown status NCT02787447 Phase 2 TKI;Thymosin Alpha 1
49 Tarceva With or Without Apatinib in the First-line Therapy of Advanced Lung Adenocarcinoma With Mutant EGFR:a Phase II Study. Unknown status NCT02704767 Phase 2 Apatinib;Tarceva;Placebo
50 Crizotinib Combined With Bevacizumab as First-line Therapy in Metastatic Lung Adenocarcinoma Cancer With ALK Translocation or MET Amplification or ROS1 Translocation (CAMAR) Unknown status NCT02946359 Phase 2 Crizotinib, bevacizumab

Search NIH Clinical Center for Lung Cancer Susceptibility 3

Cochrane evidence based reviews: adenocarcinoma of lung

Genetic Tests for Lung Cancer Susceptibility 3

Genetic tests related to Lung Cancer Susceptibility 3:

# Genetic test Affiliating Genes
1 Lung Adenocarcinoma 29

Anatomical Context for Lung Cancer Susceptibility 3

MalaCards organs/tissues related to Lung Cancer Susceptibility 3:

40
Lung, Brain, Breast, Lymph Node, Thyroid, Testes, Bone

Publications for Lung Cancer Susceptibility 3

Articles related to Lung Cancer Susceptibility 3:

(showing 14831, show less)
# Title Authors PMID Year
1
A genome-wide association study identifies two new lung cancer susceptibility loci at 13q12.12 and 22q12.2 in Han Chinese. 56
21725308 2011
2
A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. 56
19836008 2009
3
Sequence variants at the TERT-CLPTM1L locus associate with many cancer types. 56
19151717 2009
4
Lung cancer susceptibility locus at 5p15.33. 56
18978790 2008
5
Common 5p15.33 and 6p21.33 variants influence lung cancer risk. 56
18978787 2008
6
KRAS mutation, KRAS-LCS6 polymorphism, and non-small cell lung cancer. 54 61
19854534 2010
7
Comparative proteome analysis of human adenocarcinoma. 61 54
19381893 2010
8
HIF-1 alpha signaling is augmented during intermittent hypoxia by induction of the Nrf2 pathway in NOX1-expressing adenocarcinoma A549 cells. 61 54
20347035 2010
9
Comprehensive molecular analyses of lung adenocarcinoma with regard to the epidermal growth factor receptor, K-ras, MET, and hepatocyte growth factor status. 61 54
20150826 2010
10
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. 54 61
19589612 2010
11
Individuals susceptible to lung adenocarcinoma defined by combined HLA-DQA1 and TERT genotypes. 54 61
20061363 2010
12
Quantitative analysis of HGF and EGF-dependent phosphotyrosine signaling networks. 61 54
20222723 2010
13
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. 61 54
20154720 2010
14
Lung adenocarcinoma cells floating in lymphatic vessels resist anoikis by expressing phosphorylated Src. 54 61
20146241 2010
15
Down-regulation of HSP27 sensitizes TRAIL-resistant tumor cell to TRAIL-induced apoptosis. 54 61
19540014 2010
16
Secreted phosphoprotein 1 upstream invasive network construction and analysis of lung adenocarcinoma compared with human normal adjacent tissues by integrative biocomputation. 54 61
19949890 2010
17
Diagnostic value of Her-2/neu, Cyfra 21-1, and carcinoembryonic antigen levels in malignant pleural effusions of lung adenocarcinoma. 61 54
20350214 2010
18
Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. 61 54
19556604 2010
19
Correlation of F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value and EGFR mutations in advanced lung adenocarcinoma. 61 54
19130320 2010
20
Assessment of EGFR mutation status in lung adenocarcinoma by immunohistochemistry using antibodies specific to the two major forms of mutant EGFR. 61 54
20093391 2010
21
EGFR mutations and the terminal respiratory unit. 54 61
20135199 2010
22
Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. 61 54
20052735 2010
23
Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. 54 61
20007486 2010
24
Correlation between epidermal growth factor receptor mutations and expression of female hormone receptors in East-Asian lung adenocarcinomas. 61 54
19875972 2010
25
Usefulness of peptide nucleic acid (PNA)-clamp smart amplification process version 2 (SmartAmp2) for clinical diagnosis of KRAS codon 12 mutations in lung adenocarcinoma: comparison of PNA-clamp SmartAmp2 and PCR-related methods. 54 61
20007840 2010
26
Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. 61 54
19947923 2010
27
Naphtho[1,2-b]furan-4,5-dione inactivates EGFR and PI3K/Akt signaling pathways in human lung adenocarcinoma A549 cells. 61 54
20036260 2010
28
Identification and preliminary characterization of novel small molecules that inhibit growth of human lung adenocarcinoma cells. 54 61
19887599 2009
29
COLD-PCR-enhanced high-resolution melting enables rapid and selective identification of low-level unknown mutations. 61 54
19815609 2009
30
A region within the 5'-untranslated region of hypoxia-inducible factor-1alpha mRNA mediates its turnover in lung adenocarcinoma cells. 54 61
19887373 2009
31
An essential epitope of anti-MUC1 monoclonal antibody KL-6 revealed by focused glycopeptide library. 54 61
19899793 2009
32
ERCC2, ERCC1 polymorphisms and haplotypes, cooking oil fume and lung adenocarcinoma risk in Chinese non-smoking females. 54 61
20003391 2009
33
Association between polymorphisms in DNA repair genes and survival of non-smoking female patients with lung adenocarcinoma. 61 54
20003463 2009
34
Lung adenocarcinoma with EGFR amplification has distinct clinicopathologic and molecular features in never-smokers. 61 54
19826035 2009
35
Chronic exposure to exogenous matrilysin induces chemoresistance and enhances Bcl-2 expression in A549 lung adenocarcinoma cells. 61 54
19107575 2009
36
Two-round coamplification at lower denaturation temperature-PCR (COLD-PCR)-based sanger sequencing identifies a novel spectrum of low-level mutations in lung adenocarcinoma. 61 54
19760750 2009
37
Roles of pathologists in molecular targeted cancer therapy. 61 54
19891708 2009
38
Laser capture microdissection: a tool for the molecular characterization of histologic subtypes of lung adenocarcinoma. 61 54
19724887 2009
39
Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via VEGF-C. 54 61
19685508 2009
40
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. 61 54
19826477 2009
41
The cell line secretome, a suitable tool for investigating proteins released in vivo by tumors: application to the study of p53-modulated proteins secreted in lung cancer cells. 54 61
19639960 2009
42
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study. 54 61
19724844 2009
43
Dual role of poly(ADP-ribose) glycohydrolase in the regulation of cell death in oxidatively stressed A549 cells. 54 61
19571039 2009
44
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. 54 61
19794967 2009
45
Epigenetic silencing of the RASSF1A tumor suppressor gene through HOXB3-mediated induction of DNMT3B expression. 54 61
19854132 2009
46
Immunohistochemical expression of estrogen and progesterone receptors identifies a subset of NSCLCs and correlates with EGFR mutation. 54 61
19706809 2009
47
Comparison of FISH, PCR, and immunohistochemistry in assessing EGFR status in lung adenocarcinoma and correlation with clinicopathologic features. 54 61
19704257 2009
48
Cell proliferation and epidermal growth factor signaling in non-small cell lung adenocarcinoma cell lines are dependent on Rin1. 61 54
19570984 2009
49
Restoration of SOCS3 suppresses human lung adenocarcinoma cell growth by downregulating activation of Erk1/2, Akt apart from STAT3. 61 54
19524687 2009
50
Effect of yeast-derived beta-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. 61 54
19561538 2009
51
Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. 61 54
19358281 2009
52
Bronchioloalveolar carcinoma (lepidic growth) component is a more useful prognostic factor than lymph node metastasis. 61 54
19543119 2009
53
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations. 61 54
19671738 2009
54
Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. 54 61
19040416 2009
55
Alpha-tomatine inactivates PI3K/Akt and ERK signaling pathways in human lung adenocarcinoma A549 cells: effect on metastasis. 61 54
19457446 2009
56
Expression of vascular endothelial growth factors C and D correlates with lymphangiogenesis and lymph node metastasis in lung adenocarcinoma. 61 54
19629892 2009
57
Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients. 54 61
19649206 2009
58
Restoration of tumour suppressor hsa-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor receptor mutation. 61 54
19493678 2009
59
Hepatocyte growth factor induces hypoxia-related interleukin-8 expression in lung adenocarcinoma cells. 54 61
19184985 2009
60
Caveolin-1 is a novel immunohistochemical marker to differentiate epithelioid mesothelioma from lung adenocarcinoma. 61 54
19614762 2009
61
PUMA promotes Bax translocation by both directly interacting with Bax and by competitive binding to Bcl-X L during UV-induced apoptosis. 54 61
19439449 2009
62
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinoma. 61 54
19297315 2009
63
Expression of extracellular matrix molecules in brain metastasis. 61 54
19402080 2009
64
Erucin, a new promising cancer chemopreventive agent from rocket salads, shows anti-proliferative activity on human lung carcinoma A549 cells. 61 54
19328833 2009
65
Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway. 54 61
19181443 2009
66
FGFR4 Gly388Arg polymorphism may affect the clinical stage of patients with lung cancer by modulating the transcriptional profile of normal lung. 54 61
19296538 2009
67
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. 61 54
19451690 2009
68
Association of an EGFR intron 1 SNP with never-smoking female lung adenocarcinoma patients. 54 61
19026460 2009
69
Kahweol blocks STAT3 phosphorylation and induces apoptosis in human lung adenocarcinoma A549 cells. 61 54
19429240 2009
70
Clusterin silencing in human lung adenocarcinoma cells induces a mesenchymal-to-epithelial transition through modulating the ERK/Slug pathway. 61 54
19166932 2009
71
Myricetin suppresses invasion and migration of human lung adenocarcinoma A549 cells: possible mediation by blocking the ERK signaling pathway. 54 61
19326946 2009
72
[Effects of hydroquinone on expression of human 8-oxo-guanine DNA glycosylase mRNA in human A549 lung adenocarcinoma cell strains]. 54 61
19535000 2009
73
Rapid detection of matrix metalloproteinase-7 and carcinoembryonic antigen mRNA expression in intraoperative pleural lavage samples using the reverse transcriptase loop-mediated isothermal amplification method. 54 61
19534268 2009
74
Somatic alterations of the serine/threonine kinase LKB1 gene in squamous cell (SCC) and large cell (LCC) lung carcinoma. 61 54
19229701 2009
75
Micropapillary lung adenocarcinoma: EGFR, K-ras, and BRAF mutational profile. 54 61
19369630 2009
76
Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma. 54 61
18801593 2009
77
Thyroid transcription factor-1 inhibits transforming growth factor-beta-mediated epithelial-to-mesenchymal transition in lung adenocarcinoma cells. 61 54
19293183 2009
78
Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival. 54 61
19309490 2009
79
FLIM and emission spectral analysis of caspase-3 activation inside single living cell during anticancer drug-induced cell death. 54 61
19132366 2009
80
Expression of FAK and PTEN in bronchioloalveolar carcinoma and lung adenocarcinoma. 54 61
19242756 2009
81
Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma. 54 61
18931837 2009
82
Resveratrol analog-3,5,4'-trimethoxy-trans-stilbene inhibits invasion of human lung adenocarcinoma cells by suppressing the MAPK pathway and decreasing matrix metalloproteinase-2 expression. 54 61
19072741 2009
83
Stat3 downstream genes serve as biomarkers in human lung carcinomas and chronic obstructive pulmonary disease. 61 54
18614255 2009
84
The retinoblastoma gene Rb and its family member p130 suppress lung adenocarcinoma induced by oncogenic K-Ras. 61 54
19151761 2009
85
Correlation between angiogenesis and p53 expression in lung adenocarcinoma of young patients. 61 54
19212102 2009
86
Dihydroartemisinin (DHA) induces caspase-3-dependent apoptosis in human lung adenocarcinoma ASTC-a-1 cells. 54 61
19272183 2009
87
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up. 54 61
19181917 2009
88
Whole genome comparison of allelic imbalance between noninvasive and invasive small-sized lung adenocarcinomas. 54 61
19190329 2009
89
Correlation between morphology and EGFR mutations in lung adenocarcinomas Significance of the micropapillary pattern and the hobnail cell type. 54 61
18571764 2009
90
Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. 61 54
19107762 2009
91
Involvement of oxidative stress and activation of aryl hydrocarbon receptor in elevation of CYP1A1 expression and activity in lung cells and tissues by arsenic: an in vitro and in vivo study. 61 54
19033395 2009
92
Hypoxia enhances MUC1 expression in a lung adenocarcinoma cell line. 61 54
19141292 2009
93
Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma. 61 54
19096302 2009
94
VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. 54 61
19337377 2009
95
Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. 54 61
19139118 2009
96
Thyroid transcription factor 1 is an independent prognostic factor for patients with stage I lung adenocarcinoma. 61 54
19064983 2009
97
Alkaline phosphatase, cytokeratin 7, cytokeratin 8 in the diagnosis of primary lung adenocarcinoma from 148 pleura fluids specimens. 61 54
19419944 2009
98
Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer. 61 54
19154901 2009
99
TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. 54 61
19047914 2009
100
MET, HGF, EGFR, and PXN gene copy number in lung cancer using DNA extracts from FFPE archival samples and prognostic significance. 61 54
19817696 2009
101
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells. 54 61
19604037 2009
102
Absence of GAPDH regulation in tumor-cells of different origin under hypoxic conditions in - vitro. 61 54
19144146 2009
103
EGFR mutations are more frequent in well-differentiated than in poor-differentiated lung adenocarcinomas. 54 61
18985444 2008
104
An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells. 61 54
18973751 2008
105
[Effect of transfection of LKB1 on biological behavior of human lung adenocarcinoma cells]. 54 61
19068194 2008
106
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. 54 61
19060236 2008
107
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. 54 61
18794545 2008
108
Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. 61 54
19047111 2008
109
The Kras2 oncogene and mouse lung carcinogenesis. 54 61
19107609 2008
110
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. 61 54
19010870 2008
111
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. 61 54
19010923 2008
112
[Mechanism of regulation of leptin expression in human lung adenocarcinoma cells by hypoxia inducible factor-1alpha: a preliminary study]. 61 54
19080496 2008
113
Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. 54 61
18450321 2008
114
[Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer]. 61 54
19140316 2008
115
Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins. 54 61
18940913 2008
116
Different estrogen receptor beta expression in distinct histologic subtypes of lung adenocarcinoma. 61 54
18620727 2008
117
Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma. 54 61
18508816 2008
118
PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. 61 54
18678286 2008
119
The cytotoxic ribonuclease onconase targets RNA interference (siRNA). 54 61
18927512 2008
120
Expression profile of early lung adenocarcinoma: identification of MRP3 as a molecular marker for early progression. 54 61
18604784 2008
121
Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. 54 61
18776048 2008
122
[Effects of hnRNP B, siRNA on the expression of p53 in human lung adenocarcinoma cell line A549]. 54 61
19024321 2008
123
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells. 54 61
18381602 2008
124
Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. 54 61
18567995 2008
125
The histopathology of BRAF-V600E-mutated lung adenocarcinoma. 61 54
18636014 2008
126
[Relation of vascular endothelial growth factor-D expression to microvessel density, microlymphatic vessel density, and lymph-node metastasis of lung adenocarcinoma]. 61 54
19080666 2008
127
Epidermal growth factor receptor abnormalities in the pathogenesis and progression of lung adenocarcinomas. 61 54
19138956 2008
128
The value of calretinin and cytokeratin 5/6 as markers for mesothelioma in cell block preparations of serous effusions. 54 61
17916095 2008
129
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma. 54 61
18542074 2008
130
Transgenic expression of the forkhead box M1 transcription factor induces formation of lung tumors. 61 54
18345025 2008
131
The ERBB3 receptor in cancer and cancer gene therapy. 54 61
18404164 2008
132
Lung adenocarcinoma: modification of the 2004 WHO mixed subtype to include the major histologic subtype suggests correlations between papillary and micropapillary adenocarcinoma subtypes, EGFR mutations and gene expression analysis. 54 61
18391747 2008
133
[Fluorescence emission analysis of caspase-3 activation induced by Xiao-Ai-Ping (XAP) inside living human lung adenocarcinoma cells]. 61 54
18800715 2008
134
Knockdown of insulin-like growth factor 1 receptor enhances chemosensitivity to cisplatin in human lung adenocarcinoma A549 cells. 61 54
18535748 2008
135
NF-kappaB-dependent transcriptional activation in lung carcinoma cells by farnesol involves p65/RelA(Ser276) phosphorylation via the MEK-MSK1 signaling pathway. 61 54
18424438 2008
136
Association of KRAS polymorphisms with risk for lung adenocarcinoma accompanied by atypical adenomatous hyperplasias. 54 61
18299280 2008
137
Enhanced sensitivity to DNA damage induced by cooking oil fumes in human OGG1 deficient cells. 54 61
18338377 2008
138
Alteration of APE1/ref-1 expression in non-small cell lung cancer: the implications of impaired extracellular superoxide dismutase and catalase antioxidant systems. 61 54
18061304 2008
139
ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. 54 61
18399550 2008
140
c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. 61 54
18375382 2008
141
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. 61 54
18493606 2008
142
Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. 61 54
18437168 2008
143
Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. 54 61
18449007 2008
144
Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule. 61 54
17889960 2008
145
Sequential molecular changes during multistage pathogenesis of small peripheral adenocarcinomas of the lung. 54 61
18379350 2008
146
Gross cystic disease fluid protein-(GCDFP-15): expression in primary lung adenocarcinoma. 61 54
18300807 2008
147
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. 61 54
18258923 2008
148
Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma. 61 54
18303429 2008
149
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma. 54 61
18271929 2008
150
Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells. 54 61
18054347 2008
151
A subset of lung adenocarcinomas and atypical adenomatous hyperplasia-associated foci are genotypically related: an EGFR, HER2, and K-ras mutational analysis. 61 54
18208799 2008
152
siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma. 54 61
18334834 2008
153
[Quantitative analysis of thyroid transcription factor-1 mRNA expressions in primary lung cancer and its metastatic foci]. 54 61
18227018 2008
154
Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. 54 61
18199556 2008
155
Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response. 61 54
18172267 2008
156
Immunohistochemical expression of TTF-1 in various cytological subtypes of primary lung adenocarcinoma, with special reference to intratumoral heterogeneity. 61 54
18067638 2008
157
Inhibitory effect of electrolyzed reduced water on tumor angiogenesis. 61 54
18175936 2008
158
Mutational analysis of thyroid transcription factor-1 gene (TTF-1) in lung carcinomas. 61 54
18071837 2008
159
Early detection of erlotinib treatment response in NSCLC by 3'-deoxy-3'-[F]-fluoro-L-thymidine ([F]FLT) positron emission tomography (PET). 54 61
19079597 2008
160
NS-398 enhances the efficacy of gemcitabine against lung adenocarcinoma through up-regulation of p21WAF1 and p27KIP1 protein. 61 54
18348652 2008
161
Mutational analysis in cytological specimens of advanced lung adenocarcinoma: a sensitive method for molecular diagnosis. 54 61
18090579 2007
162
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. 61 54
17889445 2007
163
AMPA antagonists inhibit the extracellular signal regulated kinase pathway and suppress lung cancer growth. 54 61
18059166 2007
164
Serum carcinoembryonic antigen level is associated with epidermal growth factor receptor mutations in recurrent lung adenocarcinomas. 54 61
17941001 2007
165
Arsenic promotes centrosome abnormalities and cell colony formation in p53 compromised human lung cells. 54 61
17945324 2007
166
Modulation of tumor induction and progression of oncogenic K-ras-positive tumors in the presence of TGF- b1 haploinsufficiency. 54 61
17690114 2007
167
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. 61 54
18093943 2007
168
[Effects of RNA interference of COX-2 gene expression on malignant proliferation of A549 cells in vitro]. 61 54
18478928 2007
169
Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers. 61 54
18186961 2007
170
Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. 61 54
18006810 2007
171
Bcl-2 small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma A549/DDP cell to cisplatin and diallyl disulfide. 61 54
17989874 2007
172
Correlation between lymph node metastasis and the expression of VEGF-C, VEGF-D and VEGFR-3 in T1 lung adenocarcinoma. 61 54
17970036 2007
173
Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies. 54 61
17974985 2007
174
Angiogenic switching in the alveolar capillaries in primary lung adenocarcinoma and squamous cell carcinoma. 54 61
17965528 2007
175
Identification of a panel of sensitive and specific DNA methylation markers for lung adenocarcinoma. 61 54
17967182 2007
176
Regulation of human lung adenocarcinoma cell migration and invasion by macrophage migration inhibitory factor. 61 54
17709373 2007
177
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice. 61 54
17913856 2007
178
Neurotropin demonstrates cytoprotective effects in lung cells through the induction of thioredoxin-1. 61 54
17585112 2007
179
Mechanisms of ceramide-mediated repression of the human telomerase reverse transcriptase promoter via deacetylation of Sp3 by histone deacetylase 1. 54 61
17548428 2007
180
Usefulness of monoclonal antibody HIK1083 specific for gastric O-glycan in differentiating cutaneous metastasis of gastric cancer from primary sweat gland carcinoma. 54 61
17890913 2007
181
Microsatellite and EGFR, HER2 and K-RAS analyses in sclerosing hemangioma of the lung. 61 54
17895751 2007
182
A genetic mouse model for metastatic lung cancer with gender differences in survival. 61 54
17486075 2007
183
Activation of thromboxane receptor alpha induces expression of cyclooxygenase-2 through multiple signaling pathways in A549 human lung adenocarcinoma cells. 54 61
17632087 2007
184
Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas. 61 54
17521700 2007
185
Nras and Kras mutation in Japanese lung cancer patients: Genotyping analysis using LightCycler. 54 61
17671710 2007
186
Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells. 61 54
17569045 2007
187
Heme oxygenase-1 gene promoter polymorphism is associated with risk of gastric adenocarcinoma and lymphovascular tumor invasion. 61 54
17520317 2007
188
Transforming growth factor beta-1 enhances cytotoxic effect of doxorubicin in human lung adenocarcinoma cells of A549 line. 61 54
17418594 2007
189
TAK1 represses transcription of the human telomerase reverse transcriptase gene. 54 61
17325661 2007
190
Napsin A (TA02) is a useful alternative to thyroid transcription factor-1 (TTF-1) for the identification of pulmonary adenocarcinoma cells in pleural effusions. 61 54
17636482 2007
191
NF-kappaB inhibition by an adenovirus expressed aptamer sensitizes TNFalpha-induced apoptosis. 54 61
17560552 2007
192
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. 61 54
17726540 2007
193
Prevalence and specificity of LKB1 genetic alterations in lung cancers. 61 54
17384680 2007
194
Gene expression profiling of epidermal growth factor receptor/KRAS pathway activation in lung adenocarcinoma. 54 61
17459062 2007
195
Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human small airway epithelial cells. 61 54
17638897 2007
196
[Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. 61 54
17626761 2007
197
A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR. 54 61
17695517 2007
198
Lineage-specific dependency of lung adenocarcinomas on the lung development regulator TTF-1. 61 54
17616654 2007
199
Use of caveolin-1, thyroid transcription factor-1, and cytokeratins 7 and 20 in discriminating between primary and secondary pulmonary adenocarcinoma from breast or colonic origin. 54 61
17606426 2007
200
Distinctive evaluation of nonmucinous and mucinous subtypes of bronchioloalveolar carcinomas in EGFR and K-ras gene-mutation analyses for Japanese lung adenocarcinomas: confirmation of the correlations with histologic subtypes and gene mutations. 54 61
17580276 2007
201
c-Met activation in lung adenocarcinoma tissues: an immunohistochemical analysis. 61 54
17459054 2007
202
A micropapillary pattern is predictive of a poor prognosis in lung adenocarcinoma, and reduced surfactant apoprotein A expression in the micropapillary pattern is an excellent indicator of a poor prognosis. 54 61
17431413 2007
203
Genome-wide single nucleotide polymorphism analysis of lung cancer risk detects the KLF6 gene. 54 61
17223258 2007
204
[Expression of annexin I in different histological types of carcinomas]. 61 54
17974280 2007
205
EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung. 61 54
17487398 2007
206
Selection of DDX5 as a novel internal control for Q-RT-PCR from microarray data using a block bootstrap re-sampling scheme. 54 61
17540040 2007
207
Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells. 61 54
17492131 2007
208
Mutational analysis of EGFR and related signaling pathway genes in lung adenocarcinomas identifies a novel somatic kinase domain mutation in FGFR4. 61 54
17487277 2007
209
Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling. 61 54
17351649 2007
210
Sulforaphane sensitizes tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis through downregulation of ERK and Akt in lung adenocarcinoma A549 cells. 61 54
17183064 2007
211
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer. 61 54
17481556 2007
212
Regulation of MUC5AC expression by NAD(P)H:quinone oxidoreductase 1. 54 61
17395013 2007
213
Immunohistochemical marker panels for distinguishing between epithelioid mesothelioma and lung adenocarcinoma. 61 54
17316414 2007
214
Embryo-chondrocyte expressed gene 1, downregulating hypoxia-inducible factor 1alpha, is another marker of lung tumor hypoxia. 61 54
17376295 2007
215
Hypoxia increases the motility of lung adenocarcinoma cell line A549 via activation of the epidermal growth factor receptor pathway. 61 54
17425591 2007
216
Glycogen synthase kinase 3beta induces cell cycle arrest in a cyclin D1-dependent manner in human lung adenocarcinoma cell line A549. 61 54
17437044 2007
217
Hypoxia-inducible factor 1alpha regulates lung adenocarcinoma cell invasion. 54 61
17335808 2007
218
Ceramide induces apoptosis in human lung adenocarcinoma A549 cells through mitogen-activated protein kinases. 61 54
17303009 2007
219
Identification of trophinin as an enhancer for cell invasion and a prognostic factor for early stage lung cancer. 61 54
17254769 2007
220
Overexpressed Raf-1 and phosphorylated cyclic adenosine 3'-5'-monophosphatate response element-binding protein are early markers for lung adenocarcinoma. 61 54
17315157 2007
221
Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. 61 54
17363603 2007
222
Mesothelin expression in human lung cancer. 54 61
17332303 2007
223
MUC4 expression correlates with poor prognosis in small-sized lung adenocarcinoma. 61 54
17126950 2007
224
Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). 61 54
17240363 2007
225
Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. 54 61
17289874 2007
226
Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 up-regulation and cell growth in human lung adenocarcinomas. 54 61
17200336 2007
227
Relationship between the loss of heterozygosity and tobacco smoking in pulmonary adenocarcinoma. 54 61
17518271 2007
228
[Study on sensitivity to adriamycin of down-regulated cells expressed hOGG1 gene which target to oxidative DNA damage and repair]. 61 54
17294717 2007
229
Spatio-temporal dynamic analysis of bid activation and apoptosis induced by alkaline condition in human lung adenocarcinoma cell. 54 61
17762183 2007
230
Silencing of the type 1 insulin-like growth factor receptor increases the sensitivity to apoptosis and inhibits invasion in human lung adenocarcinoma A549 cells. 54 61
17588222 2007
231
Expression of aquaporin 3 (AQP3) in normal and neoplastic lung tissues. 54 61
17056099 2007
232
The Trk tyrosine kinase inhibitor K252a regulates growth of lung adenocarcinomas. 61 54
16862449 2007
233
Significance of an epidermal growth factor receptor mutation in cerebrospinal fluid for carcinomatous meningitis. 61 54
17917328 2007
234
Clarithromycin suppresses invasiveness of human lung adenocarcinoma cells. 61 54
17202816 2007
235
Cytochrome P450 expression (CYP) in non-small cell lung cancer. 61 54
17127240 2007
236
Effects of silencing of mutant p53 gene in human lung adenocarcinoma cell line Anip973. 61 54
17310850 2006
237
Mutational analysis of the HER2 gene in lung tumors from Caucasian patients: mutations are mainly present in adenocarcinomas with bronchioloalveolar features. 54 61
16988931 2006
238
Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. 61 54
17121895 2006
239
Reciprocal regulation of cyclooxygenase-2 and 15-hydroxyprostaglandin dehydrogenase expression in A549 human lung adenocarcinoma cells. 61 54
16632868 2006
240
Connexin 32 expression reduces malignant phenotype in human A549 adenocarcinoma cells: Implication of Src involvement. 54 61
17016607 2006
241
Relationship between N-linked oligosaccharide chains of human serum immunoglobulin G and serum tumor markers with non-small cell lung cancer progression. 61 54
17201147 2006
242
Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. 61 54
17201164 2006
243
ES1, a new lung carcinoma antibody--an immunohistochemical study. 61 54
17064298 2006
244
Clinical characterization of node-negative lung adenocarcinoma: results of a prospective investigation. 61 54
17409966 2006
245
Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. 61 54
16978197 2006
246
Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. 61 54
17003785 2006
247
Thymidine phosphorylase levels and dihydropyrimidine dehydrogenase levels in non-small cell lung cancer tissues. 61 54
16969493 2006
248
[Quantitative study of thyroid transcription factor-1 protein expression in lung carcinoma cell nucleus by tissue microarray]. 54 61
17062341 2006
249
Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. 61 54
16844092 2006
250
Rapid and simple detection of hot spot point mutations of epidermal growth factor receptor, BRAF, and NRAS in cancers using the loop-hybrid mobility shift assay. 54 61
16931592 2006
251
Role of prostaglandin E2 in the invasiveness, growth and protection of cancer cells in malignant pleuritis. 54 61
16899364 2006
252
Utility of thyroid transcription factor-1 expression in the differential diagnosis of metastatic adenocarcinoma of serous effusion specimens prepared using the cell transfer technique. 54 61
16959616 2006
253
Frequent EGFR mutations in brain metastases of lung adenocarcinoma. 61 54
16642476 2006
254
Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis. 61 54
16758298 2006
255
Effects of p73 gene overexpression on apoptosis and chemosensitivity of human lung adenocarcinoma cell line A549. 61 54
16965670 2006
256
High frequency of mutation of epidermal growth factor receptor in lung adenocarcinoma in Thailand. 61 54
16243431 2006
257
Beta-2 adrenergic receptor gene (ADRB2) polymorphism and risk for lung adenocarcinoma: a case-control study in a Chinese population. 61 54
16289313 2006
258
Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. 61 54
16518408 2006
259
Effect of connective tissue growth factor on hypoxia-inducible factor 1alpha degradation and tumor angiogenesis. 61 54
16849681 2006
260
Single nucleotide polymorphism at codon 133 of the RASSF1 gene is preferentially associated with human lung adenocarcinoma risk. 61 54
16125301 2006
261
Mitogen-activated protein kinases mediate arsenic-induced down-regulation of survivin in human lung adenocarcinoma cells. 61 54
16328441 2006
262
Carbonic anhydrase-related protein VIII increases invasiveness of non-small cell lung adenocarcinoma. 61 54
16609906 2006
263
Prognostic impact of p53 protein overexpression in patients with node-negative lung adenocarcinoma. 54 61
16102896 2006
264
Detection of epidermal growth factor receptor and human epidermal growth factor receptor 2 activating mutations in lung adenocarcinoma by high-resolution melting amplicon analysis: correlation with gene copy number, protein expression, and hormone receptor expression. 61 54
16733218 2006
265
ERBB2 kinase domain mutation in the lung squamous cell carcinoma. 61 54
16029927 2006
266
[Effect of down-regulation of survivin gene on apoptosis and cisplatin resistance in cisplatin resistant human lung adenocarcinoma A549/CDDP cells]. 54 61
17152483 2006
267
Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. A useful marker of invasive growth. 54 61
16690483 2006
268
p21Cip1 protection against hyperoxia requires Bcl-XL and is uncoupled from its ability to suppress growth. 54 61
16723699 2006
269
Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer. 61 54
16707460 2006
270
Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. 54 61
16353158 2006
271
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 54 61
16533793 2006
272
Gender difference in the activity but not expression of estrogen receptors alpha and beta in human lung adenocarcinoma cells. 54 61
16601283 2006
273
Diffuse micronodular pulmonary metastasis of lung adenocarcinoma predicts gefitinib response in association with epidermal growth factor receptor mutations. 54 61
16619582 2006
274
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. 54 61
16552419 2006
275
Anti-cancer effect of celecoxib and aerosolized docetaxel against human non-small cell lung cancer cell line, A549. 54 61
16536899 2006
276
The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. 61 54
16421102 2006
277
Caffeine stimulates the proliferation of human lung adenocarcinoma cells and small airway epithelial cells via activation of PKA, CREB and ERK1/2. 61 54
16391865 2006
278
E2F1 induces apoptosis and sensitizes human lung adenocarcinoma cells to death-receptor-mediated apoptosis through specific downregulation of c-FLIP(short). 54 61
16052233 2006
279
The Forkhead Box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. 54 61
16489016 2006
280
Transcription activity of ectogenic human carcinoembryonic antigen promoter in lung adenocarcinoma cells A549. 61 54
17219955 2006
281
Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. 61 54
16570563 2006
282
[The effect of siRNA-Her2/neu on the drug sensitivity of Her2/neu-overexpressing lung adenocarcinoma cell line]. 54 61
16638299 2006
283
Immunohistochemical alpha- and beta-catenin and E-cadherin expression and their clinicopathological significance in human lung adenocarcinoma. 61 54
16843618 2006
284
Effects of perillyl alcohol and heat shock treatment in gene expression of human lung adenocarcinoma cell line A549. 54 61
17024970 2006
285
A novel classification of MUC1 expression is correlated with tumor differentiation and postoperative prognosis in non-small cell lung cancer. 61 54
17409826 2006
286
Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. 61 54
17047397 2006
287
Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas. 61 54
16397024 2006
288
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. 54 61
16357156 2005
289
[Association of genetic polymorphism in the DNA repair gene XRCC1 with susceptibility to lung cancer in non-smoking women]. 61 54
16483478 2005
290
Pericellular activation of proMMP-7 (promatrilysin-1) through interaction with CD151. 54 61
16200075 2005
291
Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. 61 54
16367903 2005
292
Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. 61 54
16133419 2005
293
Targeting Ubc9 for cancer therapy. 61 54
16300471 2005
294
[Epidermal growth factor receptor (EGFR): therapeutic target in the treatment of lung adenocarcinoma]. 54 61
16370245 2005
295
Alternate paths from epidermal growth factor receptor to Akt in malignant versus nontransformed lung epithelial cells: ErbB3 versus Gab1. 61 54
16055672 2005
296
IGF-II induces CREB phosphorylation and cell survival in human lung cancer cells. 54 61
16158061 2005
297
The differential effects of mutant p53 alleles on advanced murine lung cancer. 54 61
16288016 2005
298
Mutations of the epidermal growth factor receptor gene in atypical adenomatous hyperplasia and bronchioloalveolar carcinoma of the lung. 61 54
15950315 2005
299
NMDA antagonist inhibits the extracellular signal-regulated kinase pathway and suppresses cancer growth. 54 61
16230611 2005
300
[Effect of RNAi-mediated gene silencing of C-erbB-2 on proliferation of lung adenocarcinoma cell line calu-3]. 61 54
16219128 2005
301
Clinical significance of vascular endothelial growth factor-C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. 61 54
16116610 2005
302
[Correlation of GLC-82 lung carcinoma cell aggregation in suspension culture to the activation of protein kinases FAK, AKT, ERK, and SRC]. 61 54
16219134 2005
303
Alteration of protein expression pattern of vascular endothelial growth factor (VEGF) from soluble to cell-associated isoform during tumourigenesis. 54 61
16202150 2005
304
Detection of disseminated lung cancer cells in regional lymph nodes by assay of CK19 reverse transcriptase polymerase chain reaction and its clinical significance. 61 54
16047189 2005
305
A polymorphism in the 5'-flanking region of the CYP2E1 gene and elevated lung adenocarcinoma risk in a Japanese population. 61 54
16142352 2005
306
Phorbol ester-induced G1 phase arrest selectively mediated by protein kinase Cdelta-dependent induction of p21. 61 54
16055435 2005
307
Establishment of an immortalized cell line from a precancerous lesion of lung adenocarcinoma, and genes highly expressed in the early stages of lung adenocarcinoma development. 61 54
16232198 2005
308
Cooking oil fumes improve lung adenocarcinoma cell survival through c-IAP2 induction. 61 54
16076764 2005
309
Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R. 54 61
16173832 2005
310
N-acetylcysteine conjugate of phenethyl isothiocyanate enhances apoptosis in growth-stimulated human lung cells. 54 61
16166335 2005
311
Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness. 61 54
15976377 2005
312
Computed tomographic images reflect the biologic behavior of small lung adenocarcinoma: they correlate with cell proliferation, microvascularization, cell adhesion, degradation of extracellular matrix, and K-ras mutation. 61 54
16153921 2005
313
Loss of TSLC1 expression in lung adenocarcinoma: relationships with histological subtypes, sex and prognostic significance. 54 61
16108829 2005
314
Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide. 61 54
15951564 2005
315
[Construction of reversed caspase-3 and it's effect on apoptosis induction in human lung adenocarcinoma cell line A549]. 54 61
16207401 2005
316
HIF-1alpha attenuates tumor growth in spite of augmented vascularization in an A549 adenocarcinoma mouse model. 54 61
16010420 2005
317
Polymorphism of the MUC1 mucin gene is associated with susceptibility to lung adenocarcinoma and poor prognosis. 54 61
15944787 2005
318
Determinants of cisplatin and irinotecan activities in human lung adenocarcinoma cells: evidence of cisplatin accumulation and topoisomerase I activity. 61 54
15999539 2005
319
Emodin induces apoptosis in human lung adenocarcinoma cells through a reactive oxygen species-dependent mitochondrial signaling pathway. 54 61
15941563 2005
320
Risk of recurrence after surgical resection of small-sized invasive lung adenocarcinoma: analysis based on apoptotic index. 61 54
16095233 2005
321
RASSF1A is not appropriate as an early detection marker or a prognostic marker for non-small cell lung cancer. 61 54
15700308 2005
322
Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. 61 54
16002952 2005
323
[Effects of Her-2/neu siRNA-mediated gene silencing on cell cycle and apoptosis of lung adenocarcinoma cells]. 61 54
16179111 2005
324
p21(Cip1/WAF1/Sdi1) does not affect expression of base excision DNA repair enzymes during chronic oxidative stress. 61 54
15890018 2005
325
Mutational analysis of EGFR and K-RAS genes in lung adenocarcinomas. 54 61
15815931 2005
326
[Proteome analysis of autoantibodies in sera of patients with cancer]. 54 61
15966408 2005
327
Expression of RUNX3 protein in human lung adenocarcinoma: implications for tumor progression and prognosis. 61 54
15819721 2005
328
[Proliferation inhibition of human lung adenocarcinoma cell line A549 transfected by RASSF1A gene]. 61 54
15898433 2005
329
[Enhancement effect of nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA on sensitivity of human lung adenocarcinoma cell line A549 to cisplatin]. 61 54
15820060 2005
330
Association of susceptibility to the development of lung adenocarcinoma with the heme oxygenase-1 gene promoter polymorphism. 61 54
15688187 2005
331
[The inhibition of 20(R)-ginsenoside Rg3 on the expressions of angiogenesis factors proteins in human lung adenocarcinoma cell line A549 and HUVEC304 cell]. 61 54
15806969 2005
332
Overexpression of soluble TRAIL induces apoptosis in human lung adenocarcinoma and inhibits growth of tumor xenografts in nude mice. 61 54
15753363 2005
333
Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. 54 61
15688028 2005
334
15-Hydroxyprostaglandin dehydrogenase can be induced by dexamethasone and other glucocorticoids at the therapeutic level in A549 human lung adenocarcinoma cells. 54 61
15680906 2005
335
Loss of function of p16 gene and prognosis of pulmonary adenocarcinoma. 61 54
15612080 2005
336
Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. 61 54
15649407 2005
337
[Effect of antisense RNA targeting Polo-like kinase 1 on cell cycle of lung cancer cell line A549]. 54 61
15694023 2005
338
Bronchioloalveolar carcinoma: a new cancer in Peutz-Jeghers syndrome. 61 54
15639728 2005
339
Napsin A is useful to distinguish primary lung adenocarcinoma from adenocarcinomas of other organs. 54 61
16259111 2005
340
Cyclin-dependent kinase 9 is required for tumor necrosis factor-alpha-stimulated matrix metalloproteinase-9 expression in human lung adenocarcinoma cells. 54 61
15528190 2005
341
Mechanical regulation of terminal chondrocyte differentiation via RGD-CAP/beta ig-h3 induced by TGF-beta. 54 61
16546826 2005
342
Effects of hypoxia on expression of P-gp and mutltidrug resistance protein in human lung adenocarcinoma A549 cell line. 54 61
16201271 2005
343
Construction of eukaryotic expression vector of human CC10 gene and expression of CC10 protein in lung adenocarcinoma A549 cell line. 54 61
16463657 2005
344
SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells. 54 61
16158247 2005
345
Regulation of CYP3A genes in the human respiratory tract. 54 61
15698577 2005
346
Effects of dexamethasone on Muc5ac mucin production by primary airway goblet cells. 61 54
15361359 2005
347
[Abrogation effect of UCN-01 on radiation-induced G2 phase arrest of tumor cells and its mechanism]. 61 54
15642191 2005
348
Altered regulation of Src upon cell detachment protects human lung adenocarcinoma cells from anoikis. 61 54
15489898 2004
349
The effects of S-phase kinase-associated protein 2 (SKP2) on cell cycle status, viability, and chemoresistance in A549 lung adenocarcinoma cells. 61 54
15700547 2004
350
Association between the risk for lung adenocarcinoma and a (-4) G-to-A polymorphism in the XPA gene. 61 54
15598786 2004
351
Methyl jasmonate induces apoptosis through induction of Bax/Bcl-XS and activation of caspase-3 via ROS production in A549 cells. 61 54
15547743 2004
352
GSTP1 affects chemoresistance against camptothecin in human lung adenocarcinoma cells. 54 61
15500952 2004
353
TTF-1 and surfactant-B as co-adjuvants in the diagnosis of lung adenocarcinoma and pleural mesothelioma. 61 54
15614737 2004
354
Polymorphism of p53 gene in Jordanian population and possible associations with breast cancer and lung adenocarcinoma. 54 61
15573180 2004
355
Selenophosphate synthetase genes from lung adenocarcinoma cells: Sps1 for recycling L-selenocysteine and Sps2 for selenite assimilation. 54 61
15534230 2004
356
Prostaglandin E2 activates Src signaling in lung adenocarcinoma cell via EP3. 61 54
15331179 2004
357
Risk for K-ras gene mutations in smoking-induced lung cancer is associated with cytochrome P4501A1 and glutathione S-transferase micro1 polymorphisms. 61 54
15375499 2004
358
Diagnostic procedures of pleural malignant mesothelioma: our experience. 54 61
17415849 2004
359
[Effects of transfected SOCS3 gene on proliferation of human lung adenocarcinoma cell line A549]. 54 61
15363199 2004
360
Immunohistochemical study of Skp2 and Jab1, two key molecules in the degradation of P27, in lung adenocarcinoma. 54 61
15363035 2004
361
[Effects of hypoxia on expression of HIF-1alpha,P53, and cyclin D1 in human lung adenocarcinoma cell line A549]. 54 61
15363196 2004
362
[Evaluation of p63 expression in lung cancer by use of complementary DNA and tissue microarray]. 61 54
15363316 2004
363
A methylated oligonucleotide induced methylation of GSTP1 promoter and suppressed its expression in A549 lung adenocarcinoma cells. 54 61
15279901 2004
364
Tetraspan and beta-1 integrins expression pattern of the epithelial lung adenocarcinoma cell line A549 and its sensitivity to divalent cations. 61 54
15221867 2004
365
[Effect of p73 gene on chemosensitivity of human lung adenocarcinoma cells H1299]. 54 61
15191663 2004
366
Plutonium targets the p16 gene for inactivation by promoter hypermethylation in human lung adenocarcinoma. 61 54
14742312 2004
367
CK20 expression, CDX2 expression, K-ras mutation, and goblet cell morphology in a subset of lung adenocarcinomas. 61 54
15141379 2004
368
ERK activation and subsequent RB phosphorylation are important determinants of the sensitivity to paclitaxel in lung adenocarcinoma cells. 54 61
15138593 2004
369
Effects of p27Kip1 on cell cycle status and viability in A549 lung adenocarcinoma cells. 61 54
15176677 2004
370
Carcinoembryonic antigen as a predictive factor for postoperative tumor relapse in early-stage lung adenocarcinoma. 54 61
15037265 2004
371
Predictive factors for survival in surgically resected clinical IA peripheral adenocarcinoma of the lung. 54 61
15063225 2004
372
The expression of c-myc, bcl-2 and p53 proteins in adenocarcinomas of lung. 54 61
20396555 2004
373
[Effects of hypoxia on expression of P-glycoprotein and multidrug resistance protein in human lung adenocarcinoma A549 cell line]. 61 54
15130309 2004
374
Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. 61 54
15102676 2004
375
Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis. 61 54
14996858 2004
376
Sulindac sulfide and caffeic acid phenethyl ester suppress the motility of lung adenocarcinoma cells promoted by transforming growth factor-beta through Akt inhibition. 61 54
14691717 2004
377
Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas. 54 61
15086970 2004
378
[The effect of Na(+)/H(+) exchanger-1 (NHE-1) antisense expression vector on NHE-1 gene expression in human lung adenocarcinoma cells and its biological significance]. 54 61
15130332 2004
379
The Cdk and PCNA domains on p21Cip1 both function to inhibit G1/S progression during hyperoxia. 61 54
12936910 2004
380
Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. 61 54
14764058 2004
381
[Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line]. 61 54
15059518 2004
382
MCM2 and Ki-67 expression in human lung adenocarcinoma: prognostic implications. 54 61
15263808 2004
383
Cyclooxygenase-2 induces EP1- and HER-2/Neu-dependent vascular endothelial growth factor-C up-regulation: a novel mechanism of lymphangiogenesis in lung adenocarcinoma. 54 61
14744769 2004
384
P-glycoprotein expression is associated with FDG uptake and cell differentiation in patients with untreated lung cancer. 61 54
15061261 2004
385
Growth pattern correlates with the distribution of basement membrane and prognosis in lung adenocarcinoma. 54 61
15462499 2004
386
Restoration of p53 tumor-suppressor activity in human tumor cells in vitro and in their xenografts in vivo by recombinant avian adenovirus CELO-p53. 54 61
14681700 2004
387
Surgical treatment of bone metastasis followed by a primary lung cancer lesion: report of a case. 61 54
15221555 2004
388
Expression of the Arp11 gene suppresses the tumorigenicity of PC-14 human lung adenocarcinoma cells. 54 61
14651955 2003
389
Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group A antisense RNA in human lung adenocarcinoma cells. 61 54
14676109 2003
390
Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. 54 61
12918063 2003
391
Cell cycle activation in lung adenocarcinoma cells by the ErbB3/phosphatidylinositol 3-kinase/Akt pathway. 54 61
12896906 2003
392
Cyclooxygenase-2 inhibition decreases primary and metastatic tumor burden in a murine model of orthotopic lung adenocarcinoma. 54 61
14566258 2003
393
Involvement of TSLC1 in progression of esophageal squamous cell carcinoma. 54 61
14559819 2003
394
Evaluation of an aerosolized selective COX-2 inhibitor as a potentiator of doxorubicin in a non-small-cell lung cancer cell line. 54 61
14567645 2003
395
Clinical implication and prognostic significance of the tumor suppressor TSLC1 gene detected in adenocarcinoma of the lung. 61 54
12942568 2003
396
Dentin matrix protein 1 is expressed in human lung cancer. 61 54
12929940 2003
397
Modulation of benzo[a]pyrene-induced p53 DNA activity by acrolein. 61 54
12807757 2003
398
The immunohistochemical diagnosis of mesothelioma: a comparative study of epithelioid mesothelioma and lung adenocarcinoma. 54 61
12883236 2003
399
Clinical evaluation of HER-2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as a tumor marker in pleural effusion diagnosis. 54 61
12855637 2003
400
Two-dimensional molecular profiling of mantle cell lymphoma. 54 61
12874873 2003
401
Automated evaluation and normalization of immunohistochemistry on tissue microarrays with a DNA microarray scanner. 54 61
12866417 2003
402
E-cadherin expression on fine-needle aspiration biopsies in primary lung adenocarcinomas is related to tumor differentiation and invasion. 61 54
12926077 2003
403
pp60c-src activation in lung adenocarcinoma. 54 61
12826049 2003
404
Ceramide accumulation precedes caspase-3 activation during apoptosis of A549 human lung adenocarcinoma cells. 54 61
12576296 2003
405
[Exogenous expression of SOCS box-deficient mutant ASB-8 suppresses the growth of lung adenocarcinoma SPC-A1 cells]. 54 61
12796816 2003
406
Analysis of NQO1, GSTP1, and MnSOD genetic polymorphisms on lung cancer risk in Taiwan. 54 61
12711112 2003
407
Association of GSTM1, CYP1A1 and CYP2E1 genetic polymorphisms with susceptibility to lung adenocarcinoma: a case-control study in Chinese population. 61 54
12824892 2003
408
Parkin, a gene implicated in autosomal recessive juvenile parkinsonism, is a candidate tumor suppressor gene on chromosome 6q25-q27. 54 61
12719539 2003
409
[Overexpression of p21WAF1 and p53 in human lung adenocarcinoma cell line]. 61 54
12905708 2003
410
Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. 54 61
12698189 2003
411
Detection and discrimination of preneoplastic and early stages of lung adenocarcinoma using hnRNP B1 combined with the cell cycle-related markers p16, cyclin D1, and Ki-67. 61 54
12660006 2003
412
Decreased tumorigenicity in vivo when transforming growth factor beta treatment causes cancer cell senescence. 61 54
12784623 2003
413
Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice. 61 54
12649187 2003
414
Regulation of CYP3A5 by glucocorticoids and cigarette smoke in human lung-derived cells. 54 61
12538830 2003
415
Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. 54 61
12644570 2003
416
Activation of phospholipase D by bradykinin and sphingosine 1-phosphate in A549 human lung adenocarcinoma cells via different GTP-binding proteins and protein kinase C delta signaling pathways. 61 54
12525155 2003
417
Expression of P53, P21 in human lung adenocarcinoma A549 cell strains under hypoxia conditions and the effect of TSA on their expression. 54 61
15015635 2003
418
Shortening of microsatellite deoxy(CA) repeats involved in GL331-induced down-regulation of matrix metalloproteinase-9 gene expression. 61 54
12559958 2003
419
Short-term depletion of catalase suppresses cadmium-elicited c-Jun N-terminal kinase activation and apoptosis: role of protein phosphatases. 61 54
12538343 2003
420
Persistent activation of ERK1/2 by lead acetate increases nucleotide excision repair synthesis and confers anti-cytotoxicity and anti-mutagenicity. 61 54
12538349 2003
421
Missense mutations of the BRAF gene in human lung adenocarcinoma. 54 61
12460919 2002
422
Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. 54 61
12414512 2002
423
Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis. 54 61
12399125 2002
424
Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. 54 61
12369871 2002
425
Association of genetic defects in primary resected lung adenocarcinoma revealed by targeted allelic imbalance analysis. 54 61
12356584 2002
426
Induction and expression of betaig-h3 in pancreatic cancer cells. 61 54
12379307 2002
427
Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. 61 54
12192603 2002
428
Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility. 61 54
12163326 2002
429
[Effect of co-inhibition of MCT1 gene and NHE1 gene on proliferation and growth of human lung adenocarcinoma cells]. 61 54
12479094 2002
430
Diagnostic utility of thyroid transcription factor-1 expression in adenocarcinomas presenting in serous fluids. 54 61
12146029 2002
431
Intrabronchial orthotopic propagation of human lung adenocarcinoma--characterizations of tumorigenicity, invasion and metastasis. 54 61
12009237 2002
432
Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin. 61 54
12479219 2002
433
Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. 61 54
11997037 2002
434
Downregulation of COX-2 and iNOS by amentoflavone and quercetin in A549 human lung adenocarcinoma cell line. 54 61
12144868 2002
435
Induction of cytochromes P450 1A1 and 1B1 in human lung adenocarcinoma CL5 cells by frying-meat emission particulate. 54 61
11955671 2002
436
De novo ceramide regulates the alternative splicing of caspase 9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein phosphatase-1. 54 61
11801602 2002
437
Antisense oligodeoxynucleotides against thrombomodulin suppress the cell growth of lung adenocarcinoma cell line A549. 54 61
11972864 2002
438
Beta IGH3, a TGF-beta inducible gene, is overexpressed in lung cancer. 61 54
11956302 2002
439
Frequent co-localization of Cox-2 and laminin-5 gamma2 chain at the invasive front of early-stage lung adenocarcinomas. 54 61
11891209 2002
440
Inhibition of cell proliferation and AP-1 activity by acrolein in human A549 lung adenocarcinoma cells due to thiol imbalance and covalent modifications. 61 54
11849044 2002
441
Thymidine phosphorylase and vascular endothelial growth factor in patients with Stage I lung adenocarcinoma. 61 54
11920479 2002
442
Arsenite pretreatment attenuates benzo[a]pyrene cytotoxicity in a human lung adenocarcinoma cell line by decreasing cyclooxygenase-2 levels. 54 61
11911489 2002
443
Inactivation of O6-methylguanine-DNA methyltransferase in human lung adenocarcinoma relates to high-grade histology and worse prognosis among smokers. 61 54
11856482 2002
444
Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of the lung. 54 61
11940214 2002
445
Human 8-oxoguanine DNA glycosylase 1 mRNA expression as an oxidative stress exposure biomarker of cooking oil fumes. 54 61
11911490 2002
446
Clinicopathologic relevance of apoptotic and proliferative factors in human lung adenocarcinoma: Fas expression correlates with the histologic subtype, but not with the degree of apoptosis. 61 54
12498219 2002
447
Protection by quercetin against cooking oil fumes-induced DNA damage in human lung adenocarcinoma CL-3 cells: role of COX-2. 61 54
12672646 2002
448
Inducible expression of endothelial PAS domain protein-1 by hypoxia in human lung adenocarcinoma A549 cells. Role of Src family kinases-dependent pathway. 54 61
11751212 2002
449
Cyclooxygenase-2 inducing Mcl-1-dependent survival mechanism in human lung adenocarcinoma CL1.0 cells. Involvement of phosphatidylinositol 3-kinase/Akt pathway. 54 61
11585835 2001
450
Loss of heterozygosity on chromosomes 9q and 16p in atypical adenomatous hyperplasia concomitant with adenocarcinoma of the lung. 54 61
11696455 2001
451
Decrease of cyclin D1 in the human lung adenocarcinoma cell line A-427 by 7-hydroxycoumarin. 61 54
11679177 2001
452
Aerogenous spread of primary lung adenocarcinoma induces ultrastructural remodeling of the alveolar capillary endothelium. 61 54
11679938 2001
453
Induction of cytochromes P450 1A1 and 1B1 by emodin in human lung adenocarcinoma cell line CL5. 61 54
11502733 2001
454
Angiogenesis and phenotypic alteration of alveolar capillary endothelium in areas of neoplastic cell spread in primary lung adenocarcinoma. 54 61
11696172 2001
455
Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. 54 61
11522641 2001
456
Opposite roles of ERK and p38 mitogen-activated protein kinases in cadmium-induced genotoxicity and mitotic arrest. 61 54
11559033 2001
457
Prostate-specific expression of Bax delivered by an adenoviral vector induces apoptosis in LNCaP prostate cancer cells. 61 54
11571575 2001
458
Glutathione S-transferase mu1 null genotype is associated with K-ras gene mutation in lung adenocarcinoma among smokers. 61 54
11470766 2001
459
Expression of nucleolar protein p120 predicts poor prognosis in patients with stage I lung adenocarcinoma. 54 61
11583194 2001
460
Immunohistochemical study with antibody to glycoprotein GCDFP-15 for metastatic lung cancer from breast cancer. 54 61
11455297 2001
461
Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. 54 61
11400116 2001
462
Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma. 54 61
11410513 2001
463
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma. 61 54
11381372 2001
464
Clinical significance of the Rb expression in adenocarcinoma of the lung. 61 54
11497280 2001
465
[Expression of tumor suppressor genes p16, p21 and p53 in a pair of lung adenocarcinoma cell lines with different metastasis potentials: Anip973 and AGZY83-a]. 61 54
11295133 2001
466
Expression of vascular endothelial growth factor receptor 3 in blood and lymphatic vessels of lung adenocarcinoma. 61 54
11276003 2001
467
c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma. 54 61
11290563 2001
468
Cytochrome P4501A2 (CYP1A2) activity and lung cancer risk: a preliminary study among Chinese women in Singapore. 54 61
11285205 2001
469
Constitutive activation of the Wnt signaling pathway by CTNNB1 (beta-catenin) mutations in a subset of human lung adenocarcinoma. 54 61
11170292 2001
470
Mucinous bronchioloalveolar carcinomas display a specific pattern of mucin gene expression among primary lung adenocarcinomas. 61 54
11274635 2001
471
Mechanisms of photoreceptor cell death in cancer-associated retinopathy. 54 61
11222531 2001
472
Alteration of cell growth and morphology by overexpression of transforming growth factor beta type II receptor in human lung adenocarcinoma cells. 61 54
11165397 2001
473
CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. 61 54
11245420 2001
474
Sole expression of laminin gamma 2 chain in invading tumor cells and its association with stromal fibrosis in lung adenocarcinomas. 54 61
11223548 2001
475
Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. 54 61
11245426 2001
476
Tumor angiogenesis and dynamic CT in lung adenocarcinoma: radiologic-pathologic correlation. 61 54
11176288 2001
477
Isolation of a novel actin-related gene expressed in low-metastatic PC-14 human lung adenocarcinoma. 54 61
11162478 2001
478
Increased retinoic acid responsiveness in lung carcinoma cells that are nonresponsive despite the presence of endogenous retinoic acid receptor (RAR) beta by expression of exogenous retinoid receptors retinoid X receptor alpha, RAR alpha, and RAR gamma. 54 61
11212249 2001
479
The XRCC1 399 glutamine allele is a risk factor for adenocarcinoma of the lung. 54 61
11104903 2001
480
Subtractive screening of genes involved in cellular senescence. 61 54
19003279 2001
481
Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis. 54 61
11145250 2001
482
Characterization of rabbit SP-B promoter region responsive to downregulation by tumor necrosis factor-alpha. 61 54
11053014 2000
483
Human tissue distribution of TA02, which is homologous with a new type of aspartic proteinase, napsin A. 54 61
11050472 2000
484
The p53 codon 72 polymorphism and lung cancer risk. 61 54
11045785 2000
485
Proximal promoter of the surfactant protein D gene: regulatory roles of AP-1, forkhead box, and GT box binding proteins. 61 54
10915785 2000
486
Co-transfection of MRP and bcl-2 antisense S-oligodeoxynucleotides reduces drug resistance in cisplatin-resistant lung cancer cells. 61 54
11775848 2000
487
Upregulation of Bcl-x and Bfl-1 as a potential mechanism of chemoresistance, which can be overcome by NF-kappaB inhibition. 54 61
11039911 2000
488
[Experimental study on combination of Ad-p53 with CDDP or As(2)O(3) in human lung adenocarcinoma cell line GLC-82]. 61 54
11798837 2000
489
Reduced expression of p27/Kip1 is associated with the development of pulmonary adenocarcinoma. 61 54
10951396 2000
490
Co-expression of epidermal growth factor receptor and transforming growth factor-alpha is independent of ras mutations in lung adenocarcinoma. 61 54
10963846 2000
491
Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. 61 54
10873096 2000
492
Mast cells correlate with angiogenesis and poor outcome in stage I lung adenocarcinoma. 54 61
10885428 2000
493
Production of functional human selenocysteine-containing KDRF/thioredoxin reductase in E. coli. 54 61
10833265 2000
494
Effect of hyperthermia on the viability and the fibrinolytic potential of human cancer cell lines. 61 54
10807968 2000
495
Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment. 61 54
10797273 2000
496
Prognostic values of stromal proportion and PCNA, Ki-67, and p53 proteins in patients with resected adenocarcinoma of the lung. 61 54
10824922 2000
497
Neutrophil elastase induces MUC5AC messenger RNA expression by an oxidant-dependent mechanism. 54 61
10843967 2000
498
Aberrant expression of photoreceptor-specific calcium-binding protein (recoverin) in cancer cell lines. 61 54
10766180 2000
499
[Applications of aryl hydrocarbon hydroxylase in diagnosis of lung cancer]. 61 54
11778487 2000
500
Prognostic significance of the size of central fibrosis in peripheral adenocarcinoma of the lung. 61 54
10750779 2000
501
Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. 54 61
10741743 2000
502
Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells. 61 54
10746741 2000
503
Paraneoplastic syndrome in the course of lung adenocarcinoma: morphological picture and immunohistochemical analysis of the inflammatory infiltrates and PECAM-1 expression. 54 61
11057031 2000
504
Dominance of ErbB-1 heterodimers in lung epithelial cells overexpressing ErbB-2. Both ErbB-1 and ErbB-2 contribute significantly to tumorigenicity. 61 54
10572067 1999
505
Napsin A, a member of the aspartic protease family, is abundantly expressed in normal lung and kidney tissue and is expressed in lung adenocarcinomas. 54 61
10580105 1999
506
Vascular endothelial growth factor and osteopontin in stage I lung adenocarcinoma. 61 54
10508818 1999
507
NAD(P)H: quinone oxidoreductase polymorphism and lung cancer in Taiwan. 54 61
10591487 1999
508
cAMP-dependent phosphorylation of betaig-h3 protein in human corneal endothelial cells. 54 61
10520231 1999
509
Prognostic value of nucleolar protein p120 in patients with resected lung adenocarcinoma. 54 61
10561346 1999
510
Expression and localization of cyclo-oxygenase isoforms in non-small cell lung cancer. 54 61
10515422 1999
511
RGD-CAP ((beta)ig-h3) enhances the spreading of chondrocytes and fibroblasts via integrin alpha(1)beta(1). 61 54
10446401 1999
512
SP-A 3'-UTR is involved in the glucocorticoid inhibition of human SP-A gene expression. 54 61
10362715 1999
513
Cytologic features based on the expression of E-cadherin and catenins in lung adenocarcinoma. 61 54
10349366 1999
514
Regulation of transforming growth factor beta1 by nitric oxide. 54 61
10232601 1999
515
MDM2 suppresses p73 function without promoting p73 degradation. 61 54
10207051 1999
516
N-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas: a ThinPrep immunocytochemical study. 54 61
10227598 1999
517
Basement membrane patterns, gelatinase A and tissue inhibitor of metalloproteinase-2 expressions, and stromal fibrosis during the development of peripheral lung adenocarcinoma. 54 61
10088553 1999
518
MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. 61 54
10215233 1999
519
[Effect of exogenous p16 gene on the growth of wild-type p53 human lung adenocarcinoma cells]. 54 61
11776846 1999
520
Detection of p53 protein accumulation in sputum and lung adenocarcinoma associated with indoor exposure to unvented coal smoke in China. 54 61
10368638 1999
521
p16 inactivation in small-sized lung adenocarcinoma: its association with poor prognosis. 54 61
9988232 1999
522
Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. 61 54
10071036 1999
523
Cytokeratin fragment 19 (CYFRA 21-1) and carcinoembryonic antigen for early prediction of recurrence of lung adenocarcinoma. 54 61
10467024 1999
524
Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy. 61 54
9927204 1999
525
Granulocyte, granulocyte-macrophage, and macrophage colony-stimulating factors can stimulate the invasive capacity of human lung cancer cells. 54 61
10408691 1999
526
Protein kinase Cdelta-dependent induction of manganese superoxide dismutase gene expression by microtubule-active anticancer drugs. 61 54
9852137 1998
527
Determination of lung as the primary site of cerebral metastatic adenocarcinomas using monoclonal antibody to thyroid transcription factor-1. 61 54
10066094 1998
528
A case of leptomeningeal metastasis from lung adenocarcinoma diagnosed by reverse transcriptase-polymerase chain reaction for carcinoembryonic antigen. 54 61
10022223 1998
529
Expression of cyclooxygenase-2 in human lung carcinoma. 54 61
9823297 1998
530
Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma. 54 61
9796717 1998
531
Prognostic significance of HER-2/neu overexpression in stage I adenocarcinoma of lung. 61 54
9800799 1998
532
Enhanced reporter gene expression in cells transfected in the presence of DMI-2, an acid nuclease inhibitor. 54 61
9930326 1998
533
Lung adenocarcinomas metastatic to the brain with and without ultrastructural evidence of rootlets: an electron microscopic and immunohistochemical study using cytokeratins 7 and 20 and villin. 61 54
9887481 1998
534
Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. 54 61
9738975 1998
535
Prognostic value of p16INK4A expression in lung adenocarcinoma. 61 54
9703871 1998
536
Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma. 61 54
9645349 1998
537
Tumor angiogenesis and vascular endothelial growth factor expression in stage I lung adenocarcinoma. 54 61
9626466 1998
538
Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. 61 54
9677444 1998
539
Villin, cytokeratin 7, and cytokeratin 20 expression in pulmonary adenocarcinoma with ultrastructural evidence of microvilli with rootlets. 61 54
9563790 1998
540
Bcl-2 and Bcl-xL in peroxide-resistant A549 and U87MG cells. 61 54
9579023 1998
541
Bronchioloalveolar carcinoma: diagnostic pitfalls and immunocytochemical contribution. 61 54
9557268 1998
542
Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. 54 61
9486981 1998
543
Cyclic AMP-responsive expression of the surfactant protein-A gene is mediated by increased DNA binding and transcriptional activity of thyroid transcription factor-1. 61 54
9468516 1998
544
Human chorionic gonadotropin and CA 15-3 producing adenocarcinoma. 61 54
9868713 1998
545
Restoration of the p16 gene is related to increased radiosensitivity of p16-deficient lung adenocarcinoma cell lines. 61 54
9860291 1998
546
The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies. 54 61
9414183 1997
547
Nuclear localization domain of thyroid transcription factor-1 in respiratory epithelial cells. 54 61
9396717 1997
548
Prognostic value of specific KRAS mutations in lung adenocarcinomas. 61 54
9332768 1997
549
The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. 61 54
9305703 1997
550
Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. 61 54
9250158 1997
551
Normal FHIT transcripts in renal cell cancer- and lung cancer-derived cell lines, including a cell line with a homozygous deletion in the FRA3B region. 54 61
9258656 1997
552
Heparin-binding properties of selenium-containing thioredoxin reductase from HeLa cells and human lung adenocarcinoma cells. 54 61
9177183 1997
553
p53, c-erbB-2 and nm23 expression have no prognostic significance in primary pulmonary adenocarcinoma. 61 54
9196297 1997
554
Regulation of surfactant protein gene expression by retinoic acid metabolites. 61 54
9128293 1997
555
Interferon gamma induces prostaglandin G/H synthase-2 through an autocrine loop via the epidermal growth factor receptor in human bronchial epithelial cells. 61 54
9062364 1997
556
Prolidase and prolinase activities in moderately and poorly differentiated lung adenocarcinoma. 54 61
9337540 1997
557
Enhancement of drug sensitivity and a bystander effect in PC-9 cells transfected with a platelet-derived endothelial cell growth factor thymidine phosphorylase cDNA. 54 61
9052401 1997
558
Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I. 54 61
9507531 1997
559
Prolidase activity and beta 1 integrin expression in moderately and poorly differentiated lung adenocarcinomas. 54 61
9337541 1997
560
Preferential radiosensitization of G1 checkpoint-deficient cells by methylxanthines. 54 61
8985032 1996
561
An immunohistochemical analysis of antioxidant and glutathione S-transferase enzyme levels in normal and neoplastic human lung. 61 54
8930626 1996
562
Enhanced urokinase-type plasminogen activator activity by extracellular matrix protein obtained from highly metastatic human lung adenocarcinoma cell line. 54 61
8879837 1996
563
Enhancement of sensitivity of human lung adenocarcinoma cells to growth-inhibitory activity of interferon alpha by differentiation-inducing agents. 61 54
8761368 1996
564
Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. 54 61
8640820 1996
565
Structural and functional analysis of the 5'-flanking region of the rat beta 2-adrenergic receptor gene. 54 61
8597598 1996
566
p16/CDKN2 gene and p53 gene alterations in Japanese non-smoking female lung adenocarcinoma. 54 61
8609061 1996
567
A new selenoprotein from human lung adenocarcinoma cells: purification, properties, and thioredoxin reductase activity. 54 61
8577704 1996
568
Characterization of the human surfactant protein D promoter: transcriptional regulation of SP-D gene expression by glucocorticoids. 61 54
8630261 1996
569
Lipid analysis and surfactant-associated protein expression in lung adenocarcinoma cells from pleural effusion. 61 54
8933661 1996
570
Expression and significance of tumoral suppressor p53 gene in lung adenocarcinomas. 61 54
9038389 1996
571
The differential expression of N-cadherin and E-cadherin distinguishes pleural mesotheliomas from lung adenocarcinomas. 61 54
8522310 1995
572
Molecular cloning of yeast cytochrome c-like polypeptide expressed in human lung carcinoma: an antigen recognizable by lung cancer-specific human monoclonal antibody. 61 54
8564085 1995
573
p53 and K-ras in radon-associated lung adenocarcinoma. 61 54
8672998 1995
574
High expression of adhesion molecules/activation markers with little interleukin-2, interferon gamma, and tumor necrosis factor beta gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma. 54 61
7641214 1995
575
Serum level and tissue expression of c-erbB-2 protein in lung adenocarcinoma. 61 54
7606952 1995
576
Expression and activation of erbB-2 and epidermal growth factor receptor in lung adenocarcinomas. 54 61
7599067 1995
577
Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent. 54 61
7784055 1995
578
Beta IG-H3, a novel secretory protein inducible by transforming growth factor-beta, is present in normal skin and promotes the adhesion and spreading of dermal fibroblasts in vitro. 54 61
7738366 1995
579
Characterization of the promoter of human pulmonary surfactant protein B gene. 61 54
7733308 1995
580
Lung surfactant protein-A and carcinoembryonic antigen in pleural effusions due to lung adenocarcinoma and malignant mesothelioma. 54 61
7789485 1995
581
The relationship between the immunodetection of transforming growth factor-beta in lung adenocarcinoma and longer survival rates. 54 61
7780613 1995
582
The mutual sparing effects of selenium and vitamin E in animal nutrition may be further explained by the discovery that mammalian thioredoxin reductase is a selenoenzyme. 54 61
8722124 1995
583
Differential down-regulation of epidermal growth factor receptors expressed in the metastatic variants of human lung cancer adenocarcinoma cell line DMS4C. 54 61
7770548 1995
584
[Sequence analysis of N--ras and p53 gene mutation in the human lung adenocarcinoma cell lines]. 61 54
7720110 1994
585
Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. 54 61
7852188 1994
586
Cathepsin B expression and laminin degradation as factors influencing prognosis of surgically treated patients with lung adenocarcinoma. 54 61
7954459 1994
587
[Advances in pathobiological research on lung carcinoma]. 61 54
7979412 1994
588
Light-dependent induction of early-response gene expression by calphostin-C. 54 61
7529661 1994
589
Loss of alpha 1 beta 1 and reduced expression of other beta 1 integrins and CAM in lung adenocarcinoma compared with pneumocytes. 54 61
7518021 1994
590
Cytologic examination and carcinoembryonic antigen assay of fine needle aspirates of bone tumors. 61 54
8042420 1994
591
beta ig-h3: a transforming growth factor-beta-responsive gene encoding a secreted protein that inhibits cell attachment in vitro and suppresses the growth of CHO cells in nude mice. 61 54
8024701 1994
592
Prognostic influence of the co-expression of epidermal growth factor receptor and c-erbB-2 protein in human lung adenocarcinoma. 61 54
7952390 1994
593
Vascular endothelial growth factor is induced in response to transforming growth factor-beta in fibroblastic and epithelial cells. 61 54
8119973 1994
594
5-Aza-2'-deoxycytidine induces growth inhibition and upregulation of epidermal growth factor receptor on human epithelial cancer cells. 54 61
7514437 1994
595
Immunohistochemical distributions of cathepsin B and basement membrane antigens in human lung adenocarcinoma: association with invasion and metastasis. 54 61
7981901 1994
596
Expression of topoisomerase II alpha and beta in an adenocarcinoma cell line carrying amplified topoisomerase II alpha and retinoic acid receptor alpha genes. 61 54
8398710 1993
597
Immunohistochemical analysis of cathepsin B expression in human lung adenocarcinoma: the role in cancer progression. 61 54
8407565 1993
598
Functional studies of a germ-line polymorphism at codon 47 within the p53 gene. 61 54
8352280 1993
599
Cytoplasmic expression of a reporter gene by co-delivery of T7 RNA polymerase and T7 promoter sequence with cationic liposomes. 61 54
8332495 1993
600
Suppression of cell motility and metastasis by transfection with human motility-related protein (MRP-1/CD9) DNA. 54 61
8478605 1993
601
[Serum levels of c-erbB-2 protein in patients with lung adenocarcinoma: preliminary report]. 54 61
8100349 1993
602
The effect of thrombospondin on invasion of fibrin gels by human A549 lung carcinoma. 61 54
8305744 1993
603
Selective regulation of beta 2-adrenergic receptor gene expression by interleukin-1 in cultured human lung tumor cells. 54 61
1324243 1992
604
Characterization of the mucin differentiation in human lung adenocarcinoma cell lines. 54 61
1497905 1992
605
cis-acting elements that confer lung epithelial cell expression of the CC10 gene. 54 61
1634515 1992
606
Post-transcriptional regulation of the human transforming growth factor-beta 1 gene. 54 61
1618868 1992
607
Urokinase-type plasminogen activator and its specific receptor in high metastatic and non-metastatic cell lines derived from human lung adenocarcinoma. 61 54
1321513 1992
608
An evaluation of the prognostic significance of alpha-1-antitrypsin expression in adenocarcinomas of the lung: an immunohistochemical analysis. 61 54
1739634 1992
609
Regulation of amphiregulin mRNA by TGF-beta in the human lung adenocarcinoma cell line A549. 54 61
1457126 1992
610
Immunohistochemical evidence of urokinase-type plasminogen activator in primary and metastatic tumors of pulmonary adenocarcinoma. 61 54
2054790 1991
611
Drug effects on CA125 antigen expression and antibody binding to cancer cells. 61 54
1645702 1991
612
Regulation of transforming growth factor beta 1 gene expression by the product of the retinoblastoma-susceptibility gene. 61 54
1901652 1991
613
Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma. 61 54
1683776 1991
614
[The effect of epidermal growth factor and insulin on the specific binding of transforming growth factor beta by NRK-49F and A-459 cell lines]. 54 61
1666203 1991
615
Use of conditioned media in cell culture can mask cytogenetic abnormalities in acute leukemia. 61 54
2331674 1990
616
[The effect of transforming growth factor beta on the intensity of cellular DNA synthesis in relation to the type and conditions of cultivation]. 61 54
2195726 1990
617
Competing endogenous RNA network profiling reveals novel host dependency factors required for MERS-CoV propagation. 61
32223537 2020
618
Heparan sulfate targeting strategy for enhancing liposomal drug accumulation and facilitating deep distribution in tumors. 61
32241176 2020
619
FAM136A immunoreactivity is associated with nodal involvement and survival in lung adenocarcinoma in a Chinese case series. 61
32098576 2020
620
Dendritic cells in tumor microenvironment promoted the neuropathic pain via paracrine inflammatory and growth factors. 61
32434423 2020
621
Preparation and antitumor evaluation of hinokiflavone hybrid micelles with mitochondria targeted for lung adenocarcinoma treatment. 61
32252563 2020
622
KANK1 regulates paclitaxel resistance in lung adenocarcinoma A549 cells. 61
32064933 2020
623
lncRNA Metastasis-Associated Lung Adenocarcinoma Transcript 1 Promotes Proliferation and Invasion of Non-Small Cell Lung Cancer Cells via Down-Regulating miR-202 Expression. 61
31863664 2020
624
Contributions and prognostic values of m6 A RNA methylation regulators in non-small-cell lung cancer. 61
32052446 2020
625
LncRNA MALAT1 mediates proliferation of LPS treated-articular chondrocytes by targeting the miR-146a-PI3K/Akt/mTOR axis. 61
31472145 2020
626
Highly efficient Pyrococcus furiosus recombinant L-asparaginase with no glutaminase activity: Expression, purification, functional characterization, and cytotoxicity on THP-1, A549 and Caco-2 cell lines. 61
32311402 2020
627
Histological and prognostic data on surgically resected early-stage lung adenocarcinoma. 61
32551350 2020
628
A comprehensive study of construction and analysis of competitive endogenous RNA networks in lung adenocarcinoma. 61
32423886 2020
629
A milbemycin compound isolated from Streptomyces Sp. FJS31-2 with cytotoxicity and reversal of cisplatin resistance activity in A549/DDP cells. 61
32505822 2020
630
Preoperative biopsy and tumor recurrence of stage I adenocarcinoma of the lung. 61
31873771 2020
631
An extremely rare case of nivolumab-associated macroscopic duodenitis with spontaneous regression. 61
32405415 2020
632
Developing an Arrayed CRISPR-Cas9 Co-Culture Screen for Immuno-Oncology Target ID. 61
32375580 2020
633
Less immune cell infiltration and worse prognosis after immunotherapy for patients with lung adenocarcinoma who harbored STK11 mutation. 61
32413741 2020
634
Radiomics-based prediction for tumour spread through air spaces in stage I lung adenocarcinoma using machine learning. 61
32011674 2020
635
Temporal Heterogeneity of Resistance Mechanisms to EGFR-TKI Identified in a Patient With Lung Adenocarcinoma and Sarcomatoid Transformation. 61
32122806 2020
636
Diagnostic value and imaging features of multi-detector CT in lung adenocarcinoma with ground glass nodule patients. 61
32565994 2020
637
Leveraging methylation to identify the potential causal genes associated with survival in lung adenocarcinoma and lung squamous cell carcinoma. 61
32537022 2020
638
Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma. 61
32272148 2020
639
Correlation between the expression of folate receptor alpha (FRα) and clinicopathological features in patients with lung adenocarcinoma. 61
32450493 2020
640
A cross-modal 3D deep learning for accurate lymph node metastasis prediction in clinical stage T1 lung adenocarcinoma. 61
32387813 2020
641
Development and validation of a five-gene model to predict postoperative brain metastasis in operable lung adenocarcinoma. 61
32181877 2020
642
A Preliminary Study of Adoptive T-cell Transfer Therapy for Patients With Non-Small-cell Lung Adenocarcinoma With Brain Metastasis: A Case Report of 3 Patients. 61
32192894 2020
643
The study of effect and mechanism of 630-nm laser on human lung adenocarcinoma cell xenograft model in nude mice mediated by hematoporphyrin derivatives. 61
31642999 2020
644
Immuno-SPECT/PET imaging with radioiodinated anti-PD-L1 antibody to evaluate PD-L1 expression in immune-competent murine models and PDX model of lung adenocarcinoma. 61
32474281 2020
645
YRDC is upregulated in non-small cell lung cancer and promotes cell proliferation by decreasing cell apoptosis. 61
32565932 2020
646
The diagnostic efficiency of seven autoantibodies in lung cancer. 61
31764214 2020
647
Proton magnetic resonance spectroscopy of lung cancer in vivo. 61
32489513 2020
648
Prognostic significance of an invasive leader cell-derived mutation cluster on chromosome 16q. 61
32315457 2020
649
EGFR-mutated lung adenocarcinomas from patients who progressed on EGFR-inhibitors show high engraftment rates in xenograft models. 61
32447118 2020
650
Comprehensive analysis of the expression and prognosis for TFAP2 in human lung carcinoma. 61
32462520 2020
651
MALAT1 knockdown inhibits hypopharyngeal squamous cell carcinoma malignancy by targeting microRNA-194. 61
32565945 2020
652
LncRNA-Malat1 is Involved in Lipotoxicity-Induced ß-cell Dysfunction and the Therapeutic Effect of Exendin-4 via Ptbp1. 61
32324218 2020
653
Optimization of CT windowing for diagnosing invasiveness of adenocarcinoma presenting as sub-solid nodules. 61
32371183 2020
654
Radiomics nomogram for preoperative differentiation of lung tuberculoma from adenocarcinoma in solitary pulmonary solid nodule. 61
32371184 2020
655
Preoperative CT-based Deep Learning Model for Predicting Disease-Free Survival in Patients with Lung Adenocarcinomas. 61
32396042 2020
656
Prognostic impact of cancer-associated active fibroblasts and invasive architectural patterns on early-stage lung adenocarcinoma. 61
32450494 2020
657
An individualised radiomics composite model predicting prognosis of stage 1 solid lung adenocarcinoma. 61
32307110 2020
658
A novel EML4-ALK BIRC6-ALK double fusion variant in lung adenocarcinoma confers sensitivity to alectinib. 61
32409002 2020
659
Intraparotid metastasis from lung adenocarcinoma diagnosed by FNAC-Report of a rare case. 61
32298526 2020
660
Miliary lung metastases from ROS1-rearranged lung adenocarcinoma: A case report. 61
32454978 2020
661
A quantitative imaging biomarker for predicting disease-free-survival-associated histologic subgroups in lung adenocarcinoma. 61
32086583 2020
662
CT-based radiomics and machine learning to predict spread through air space in lung adenocarcinoma. 61
32112116 2020
663
Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis. 61
32189030 2020
664
Radiomics for lung adenocarcinoma manifesting as pure ground-glass nodules: invasive prediction. 61
32162003 2020
665
Multiple intracranial lesions with lung adenocarcinoma: A rare case of MOG-IgG-associated encephalomyelitis. 61
32234600 2020
666
EGFR-mutant lung adenocarcinoma harboring co-mutational tumor suppressor genes predicts poor prognosis. 61
32361787 2020
667
MICAL2 is a novel nucleocytoplasmic shuttling protein promoting cancer invasion and growth of lung adenocarcinoma. 61
32360180 2020
668
Comprehensive Analysis of Aberrantly Expressed Profiles of lncRNAs and miRNAs with Associated ceRNA Network in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma. 61
31898160 2020
669
Puerarin 6″-O-xyloside suppresses growth, self-renewal and invasion of lung cancer stem-like cells derived from A549 cells via regulating Akt/c-Myc signalling. 61
32124474 2020
670
A user's guide to lorlatinib. 61
32416346 2020
671
Nuclear Cytoplasmic Inclusions in Lung Adenocarcinoma: Relevance of Immunohistochemistry. 61
31428992 2020
672
Suppression of long non-coding RNA MALAT1 inhibits survival and metastasis of esophagus cancer cells by sponging miR-1-3p/CORO1C/TPM3 axis. 61
32468237 2020
673
Pembrolizumab-induced secondary sclerosing cholangitis in a non-small cell lung cancer patient. 61
32284868 2020
674
MUC5AC enhances tumor heterogeneity in lung adenocarcinoma with mucin production and is associated with poor prognosis. 61
32083303 2020
675
Correlation between PD-L1 expression (clones 28-8 and SP263) and histopathology in lung adenocarcinoma. 61
32514486 2020
676
Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas. 61
32237253 2020
677
The ADAM17 protease promotes tobacco smoke carcinogen-induced lung tumorigenesis. 61
31257400 2020
678
68Ga-FAPI PET/CT Improves Therapeutic Strategy by Detecting a Second Primary Malignancy in a Patient With Rectal Cancer. 61
32149789 2020
679
Epigenome-wide gene-age interaction analysis reveals reversed effects of PRODH DNA methylation on survival between young and elderly early-stage NSCLC patients. 61
32511103 2020
680
Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context". 61
32169258 2020
681
[HRCT features differentiate synchronous multiple primary lung adenocarcinomas from intrapulmonary metastases]. 61
32575939 2020
682
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions. 61
32122926 2020
683
Gas chromatography-mass spectrometry (GM-MS) analysis and biological activities of the aerial part of Cleome amblyocarpa Barr. and Murb. 61
32323234 2020
684
Napsin A is a highly sensitive marker for nephrogenic adenoma: an immunohistochemical study with specificity test in genitourinary tumors. 61
32561332 2020
685
Long non-coding RNA MALAT1/microRNA 125a axis presents excellent value in discriminating sepsis patients and exhibits positive association with general disease severity, organ injury, inflammation level, and mortality in sepsis patients. 61
32309886 2020
686
Screening of miRNAs associated with lymph node metastasis in Her-2-positive breast cancer and their relationship with prognosis. 61
32478495 2020
687
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy. 61
32540560 2020
688
PDB-1 from Potentilla discolor Bunge induces apoptosis and autophagy by downregulating the PI3K/Akt/mTOR signaling pathway in A549 cells. 61
32544818 2020
689
The expression of lncRNA-MALAT1 in breast cancer patients and its influences on prognosis. 61
32538750 2020
690
Proteomic analysis enables distinction of early- versus advanced-stage lung adenocarcinomas. 61
32536039 2020
691
Comprehensive analyses of T-UCR expression profiles and exploration of the efficacy of uc.63- and uc.280+ as biomarkers for lung cancer in Xuanwei, China. 61
32360249 2020
692
Association of lncRNA-p53 regulatory network (lincRNA-p21, lincRNA-ROR and MALAT1) and p53 with the clinicopathological features of colorectal primary lesions and tumors. 61
32391102 2020
693
The lncRNA ANRIL is down-regulated in peripheral blood of patients with periodontitis. 61
32346660 2020
694
Temporal trend of arsenic in outdoor air PM2.5 in Wuhan, China, in 2015-2017 and the personal inhalation of PM-bound arsenic: implications for human exposure. 61
32279249 2020
695
Non-amplification genetic alterations of HER2 gene in non-small cell lung carcinoma. 61
32527755 2020
696
Association of serine/threonine kinase 11 mutations and response to programmed cell death 1 inhibitors in metastatic gastric cancer. 61
32284250 2020
697
Low expression of RGL4 is associated with a poor prognosis and immune infiltration in lung adenocarcinoma patients. 61
32259700 2020
698
KRT8 and KRT19, associated with EMT, are hypomethylated and overexpressed in lung adenocarcinoma and link to unfavorable prognosis. 61
32519739 2020
699
Identification of Novel CD74-NRG2α Fusion From Comprehensive Profiling of Lung Adenocarcinoma in Japanese Never or Light Smokers. 61
32036070 2020
700
Anti-Tumor Effects of Biomimetic Sulfated Glycosaminoglycans on Lung Adenocarcinoma Cells in 2D and 3D In Vitro Models. 61
32503108 2020
701
Oncologic outcomes of segmentectomy vs lobectomy in pathologic stage IA (≤2 cm) invasive lung adenocarcinoma: A population-based study. 61
32108349 2020
702
Targeting alveolar macrophages shows better treatment response than deletion of interstitial macrophages in EGFR mutant lung adenocarcinoma. 61
32125091 2020
703
A putative competing endogenous RNA network in cisplatin-resistant lung adenocarcinoma cells identifying potentially rewarding research targets. 61
32382346 2020
704
Comprehensive analysis of gene expression and DNA methylation data identifies potential biomarkers and functional epigenetic modules for lung adenocarcinoma. 61
32484849 2020
705
Integrated analysis of miRNAs and DNA methylation identifies miR-132-3p as a tumor suppressor in lung adenocarcinoma. 61
32500672 2020
706
Novel NLRC4-ALK and EML4-ALK double fusion mutations in a lung adenocarcinoma patient: A case report. 61
32212216 2020
707
LTBP1-ALK: A novel fusion identified in malignant pleural effusions from a patient with advanced lung adenocarcinoma. 61
32299643 2020
708
HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model. 61
32353632 2020
709
A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation. 61
32356218 2020
710
miR‑10a increases the cisplatin resistance of lung adenocarcinoma circulating tumor cells via targeting PIK3CA in the PI3K/Akt pathway. 61
32186774 2020
711
Combined Evaluation of Tumor-Infiltrating CD8 + and FoxP3 + Lymphocytes Provides Accurate Prognosis in Stage IA Lung Adenocarcinoma. 61
31773516 2020
712
Transcription factor RUNX3 promotes CD8+ T cell recruitment by CCL3 and CCL20 in lung adenocarcinoma immune microenvironment. 61
31898342 2020
713
Clinical significance and inflammatory landscapes of a novel recurrence-associated immune signature in early-stage lung adenocarcinoma. 61
32201203 2020
714
High Expression of FGF5 Is an Independent Prognostic Factor for Poor Overall Survival and Relapse-Free Survival in Lung Adenocarcinoma. 61
31553229 2020
715
Absence of HTATIP2 Expression in A549 Lung Adenocarcinoma Cells Promotes Tumor Plasticity in Response to Hypoxic Stress. 61
32545251 2020
716
ALK-rearranged lung adenocarcinoma transformation into high-grade large cell neuroendocrine carcinoma: Clinical and molecular description of two cases. 61
32546380 2020
717
Overexpression of FYN suppresses the epithelial-to-mesenchymal transition through down-regulating PI3K/AKT pathway in lung adenocarcinoma. 61
32561075 2020
718
Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation. 61
32543264 2020
719
Impact of T-cell receptor and B-cell receptor repertoire on the recurrence of early stage lung adenocarcinoma. 61
32540399 2020
720
Hybrid Clinical-Radiomics Model for Precisely Predicting the Invasiveness of Lung Adenocarcinoma Manifesting as Pure Ground-Glass Nodule. 61
32534967 2020
721
The prognostic significance of CLEC-2-related gene signal in lung adenocarcinoma: A multicenter development and validation cohort. 61
32535970 2020
722
Immune landscape and a novel immunotherapy-related gene signature associated with clinical outcome in early-stage lung adenocarcinoma. 61
32333046 2020
723
Whole exome sequencing of lung adenocarcinoma and lung squamous cell carcinoma in one individual: A case report. 61
32578383 2020
724
One-Step Microfluidic Coating of Phospholipid Microbubbles with Natural Alginate Polymer as a Delivery System for Human Epithelial Lung Adenocarcinoma. 61
32346989 2020
725
ASCL1 promotes tumor progression through cell-autonomous signaling and immune modulation in a subset of lung adenocarcinoma. 61
32534174 2020
726
Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma. 61
32556504 2020
727
Successful treatment of an osimertinib-resistant lung adenocarcinoma with an exon 18 EGFR mutation (G719S) with afatinib plus bevacizumab. 61
32556898 2020
728
Mortal Obligate RNA Transcript Inhibits Cancer Cell Invasion and Migration in Lung Adenocarcinoma by Downregulating miRNA-223. 61
32160014 2020
729
Comprehensive Analysis of Competing Endogenous RNA (ceRNA) Network Based on RNAs Differentially Expressed in Lung Adenocarcinoma Using The Cancer Genome Atlas (TCGA) Database. 61